Medicines and poisons
Medicines and Poisons is responsible for the monitoring and control of supply of scheduled substances in the Northern Territory (NT).
The following areas come under Medicines and Poisons and can be found on these pages or on the NT Government website:
- medicines and poisons for retailers, wholesalers and manufacturers
- medicines and poisons safety
- gazette notices
- medical kits
- pest management technicians
- pharmacists
- scheduled substances
- veterinarians.
Legislation
Medicines and poisons enforces compliance of these Acts:
- Medicines, Poisons and Therapeutic Goods Act 2012
- Private Hospitals Act 1981
- Health Practitioners Act 2004.
Role
The Medicines and Poisons program has these key responsibilities:
- issuing licences, registrations and authorisations under the relevant Acts
- inspecting premises for compliance storage, record keeping, packaging, labelling, advertising and supply
- scheduling of poisons and medicines
- monitoring the movement of S8 medicines
- issuing authorisations for the NT Opiate Pharmacotherapy Program
- secretariat support for the Department of Health statutory committees:
Contact
Medicines and Poisons
8th floor Manunda Place
38 Cavenagh Street
Darwin NT 0800
Phone: 08 8922 7341
Fax: 08 8922 7200
poisonscontrol@nt.gov.au
PO Box 40596
Casuarina NT 0811
Medicines and poisons notices
This page contains notices relating to the Medicines, Poisons and Therapeutic Goods Act 2012.
For COVID-19 vaccination administration protocols, go to the COVID-19 vaccine protocols page.
The notices allow certain health practitioners to possess, administer and supply scheduled substances under protocol.
Organisations outside NT Health need to use one of these application forms to apply for a new approval or request an update to an existing approval. The completed form and all attachments must be emailed to poisonscontrol@nt.gov.au
Document | Sponsoring area | Health practitioner | Date |
---|---|---|---|
Resqmed Paramedic | Medicines and Poisons, NT Health | Paramedics | 18 March 2024 |
Menzies Vaccination | Medicines and Poisons, NT Health | Nurses, Midwives, Aboriginal Health Practitioners | 11 March 2024 |
DPH Staff Vaccination | Medicines and Poisons, NT Health | Nurses, Midwives | 6 March 2024 |
NT Health Paramedic | Chief Executive, NT Health | Paramedics | 14 December 2023 |
Pharmacist Vaccination | Medicines and Poisons, NT Health | Pharmacists | 8 December 2023 |
PPHC Remote SSTP | NT Health Remote Primary and Population Health Care clinics and health centres | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 9 October 2023 |
Aspen Medical - Barkly minesites | Aspen Medical | Nurses and paramedics | 21 June 2023 |
Teck Australia SSTP - Barkly Tenements | Teck Australia | Paramedic | 2 May 2023 |
Vitality Works SSTP | Vitality Works | Nurses and midwives | 19 May 2023 |
Aspenmedical SSTP | Aspenmedical - Wickham Point | Nurses and paramedics | 18 May 2023 |
ACCHO - SSTP | Non-government community health centres and clinics | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 8 May 2023 |
Parabellum SSTP | Parabellum International | Paramedic | 3 May 2023 |
SARC SSTP | Chief Health Officer | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 14 March 2023 |
MPox SSTP | Chief Health Officer | Aboriginal and Torres Strait Islander health practitioners, midwives, nurses and pharmacists | 14 March 2023 |
JE SSTP | Chief Health Officer | Aboriginal and Torres Strait Islander health practitioners, midwives, nurses and pharmacists | 14 March 2023 |
MPTGA S254 | Darwin Private Hospital | Staff vaccinations | 2 March 2023 |
G16 2022 | BizHealth Consultants Pty Ltd | Nurses | 20 April 2022 |
S15 2022 | HCA Corporate Health Pty Ltd | Nurses | 14 April 2022 |
G6 2022 p3-4 | Immunisation - qualifications | Pharmacists | 9 February 2022 |
G51 2021 p7-8 | Darwin Day Surgery and Golden Glow Corporation | Nurses | 16 December 2021 |
G46 2021 p2-10 | Immunisation - prescribed qualifications to supply, administer or possess vaccines | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 17 November 2021 |
G44 2021 p7-17 | Centre for Disease Control – Meningococcal B Vaccine Study “B Part of it NT” | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 3 November 2021 |
G34 2021 p8-11 | Oral Health Services | Dental Therapist, Dental Hygienist or Oral Health Therapist | 25 August 2021 |
G29 2021 p2-4 | Royal Flying Doctor Service | Nurses and Midwives | 21 July 2021 |
G23 2021 p6-9 | Darwin Occupational Services (DOS) | Nurses | 9 June 2021 |
S12 2021 | Medimobile | Nurses | 6 May 2021 |
G18 2021 - p1-4 | Urban Schools | Nurses and Midwives | 5 May 2021 |
G13 2021 p4-7 | Public Hospital Maternity | Midwives | 31 March 2021 |
G11 2021 p1-4 | Urban Community Health Clinics | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 17 March 2021 |
S2 2021 | Chief Health Officer Covid-19 response – declared site Darwin | 15 January 2021 | |
G39 2020 p4 | Chief Health Officer Covid-19 response – declared sites Alice Springs and Tennant Creek | 30 September 2020 | |
G26 2020 p10-11 | RDH ENT outpatient - declarations and approval | Nurse and Midwives | 1 July 2020 |
G20 2020 p4-7 | Renal Services | Aboriginal and Torres Strait Islander health practitioners and nurses | 20 May 2020 |
G16 2020 | Howard Springs facility declared place | 22 April 2020 | |
G13 2020 | SMG Health | Nurses | 1 April 2020 |
S22 2019 | CareFlight | Nurses, Midwives and Paramedics | 12 April 2019 |
S108 2018 | AusHealth Corporate Pty Ltd | Nurse and Midwives | 19 December 2018 |
S81 2018 | Northern Territory Alcohol and Drug Services | Nurse and Midwives | 5 October 2018 |
S55 2018 | Correctional facilities centres and clinics | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 18 July 2018 |
S81 2017 | Centre for Disease Control (CDC) - Immunisation | Aboriginal and Torres Strait Islander health practitioners, midwives and nurses | 10 Nov 2017 |
S94 2016 | Sonic Healthplus Darwin | Nurses | 17 Aug 2016 |
S28 2016 | NT Renal Services | Nurses and Midwives | 14 April 2016 |
S22 2016 | VaxWorks Health Services Pty Ltd | Nurses and Midwives | 7 April 2016 |
Alice Springs Hospital Emergency Department | Nurses and Midwives | 6 May 2015 | |
S36 2015 p4-5 | Infection Prevention and Management Units | Nurses and Midwives | 23 Apr 2015 |
S35 2015 p9-10 | Immunisation - Approval of SSTP for NCCTRC | Pharmacists | 21 Apr 2015 |
Primary Health Care, DoH - Police Stations and Watchhouses | Nurses and Midwives | 17 Mar 2015 | |
Centre for Disease Control (CDC) - Extra vaccines and medicines | Aboriginal and Torres Strait Islander health practitioners | 25 Jun 2014 | |
G25 2014 | Centre for Disease Control (CDC) - Extra vaccines and medicines | Nurses and Midwives | 25 Jun 2014 |
Home Birth Services | Midwives | 30 Mav 2014 | |
Family Planning Welfare NT (FPWNT) | Nurses and Midwives | 1 May 2014 |
The following Government Gazettes mark the commencement of Medicines, Poisons and Therapeutic Goods Act 2012, in 2014.
Title | Content | Date |
---|---|---|
Assent to Proposed Laws Medicines, Poisons and Therapeutic Goods Amendment Act (No 12 of 2014) | 30 Apr 2014 | |
Declared Medical Conditions | 23 Apr 2014 | |
Approval for Pharmacist to Supply S8 Substances on Interstate Prescription (Cross-Border Communities) | 23 Apr 2014 | |
G15 2014 | Notification of Subordinate Legislation - Medicines, Poisons and Therapeutic Goods Regulations | 16 Apr 2014 |
S8 Code of Practice and related documents
Title | Content | Date |
---|---|---|
Section 243E | Exemption from requirement to give information | 17 December 2021 |
S42 2021 | Exemption - S8 authorisation - During Emergency response - Medical practitioners and nurse practitioners Psychostimulants | 7 December 2021 |
G10 2020 p2 | Notice of making S8 Code of Practice – new edition of Part 4 Opioid Substitution Treatment | 11 March 2020 |
G10 2020 p3 | Declaration of Restricted S8 Substances | 11 March 2020 |
G26 2020 p12-14 | Exemption - S8 Authorisation for hospital patients | 1 July 2020 |
G26 2020 p15-16 | Exemption - S8 Authorisation - Authorised Health Practitioners at AODS and Corrections | 1 July 2020 |
G26 2020 p17-18 | Exemption - S8 Authorisation - Methadone liquid for patients in intensive care | 1 July 2020 |
G26 2020 p19-20 | Exemption - S8 Authorisation - Methadone liquid for palliative care patients | 1 July 2020 |
G26 2020 p21-23 | Exemption - S8 Authorisation - Patient transfers to and from AODS and corrections | 1 July 2020 |
G26 2020 p24-27 | Exemption - S8 Authorisation - Shared care providers - Patient transfers to and from AODS and corrections | 1 July 2020 |
G17 of 2014 (4/17) p3 | Exemption – S8 Authorisation – Prescribe psychostimulant in absence of authorised specialised prescriber in group practice/as locum | 30 April 2014 |
Medical practitioners and schedule 8 medicines
This page has information for medical practitioners about the prescription and supply of Schedule 8 (S8) substances.
The Medicines, Poisons and Therapeutic Goods Act 2012 states that the following applies to medical practitioners:
- authorised prescribers, including doctors, nurse practitioners, eligible midwives, dentists and veterinarians, are prohibited from prescribing a S8 substance to themselves
- prescribers must check the Monitored Medicines database (NTScript) prior to issuing a prescription for a monitored medicine
- the Chief Health Officer (CHO) can also declare Schedule 4 substances to be restricted if additional controls are needed to ensure safe access and use.
For information about the use prescribing contracts list please contact Medicines and Poisons during office hours on (08) 89227 341 or by emailing poisonscontrol@nt.gov.au
Read about the laws that apply to S8 drugs in the S8 Code of Practice, further down this page.
Restricted S8 substances
S8 substances are classified as either restricted or unrestricted.
Restricted S8 substances include:
- buprenorphine depot Injections (Buvidal® and Sublocade®)
- buprenorphine (Subutex®) 0.4mg, 2mg and 8mg for sublingual administration
- buprenorphine/naloxone (Suboxone®) 2mg/0.5mg, 8mg/2mg in film form for sublingual or buccal administration
- methadone liquid 5mg/mL for oral administration
- dexamfetamine
- lisdexamfetamine
- methylphenidate.
Supply
The following applies for the supply of dexamphetamine, lisdexamfetamine and methylphenidate:
- authorisation from the CHO is required for each individual patient before a prescription can be issued
- only paediatricians, psychiatrists, physicians, neurologists and registrars in training in these disciplines may make the decision to initiate supply
- other medical practitioners may continue supply after one of the above specialists or registrars has done so
- under such a co-management situation the patient must be seen by a specialist or registrar at least every two years
- specialists may initiate supply without an authorisation, but must obtain an authorisation if supply exceeds 30 days.
The following applies for the supply of buprenorphine (Subutex®), buprenorphine/naloxone (Suboxone®), buprenorphine depot Injections (Buvidal® and Sublocade®) and methadone liquid:
- medical practitioners providing pharmacotherapies for opioid dependence need to complete approved training initially and demonstrate continued clinical involvement and the undertaking of refresher training
- an authority from the CHO to supply buprenorphine, buprenorphine/naloxone, buprenorphine depot injections and methadone is required for each individual patient before a prescription can be written or supplied
- the framework for supply of these medications covers the writing of prescriptions, details of authorisation requirements, period of supply, dispensing of medications and takeaway privileges.
Unrestricted S8 substances
Unrestricted S8 substances includes common analgesics such as morphine, oxycodone and tapentadol as well as some benzodiazepines such as alprazolam.
Supply
The following applies for the supply of unrestricted substances:
- medical practitioners may supply unrestricted S8 substances for the treatment of medical and surgical conditions but not for the treatment of addiction
- a medical practitioner may only supply unrestricted S8 substances for up to 15 patients at a time
- this number does not include patients receiving palliative care in end of life situation, hospital inpatients or those in need of emergency treatment
- a medical practitioner may apply to the CHO for an authority to prescribe unrestricted S8 substances for more than this number of patients
- medical practitioners must notify the CHO of the supply of unrestricted S8 substances under certain circumstances, for example if supply exceeds 8 weeks, if certain dosage levels are exceeded or if their circumstances may be conducive to possible abuse.
Electronic Prescribing
The NT permits electronic prescriptions for all Schedule 4 and Schedule 8 medicines in accordance with the Electronic Transactions (Northern Territory) Act 2000.
This includes for interstate prescriptions and prescriptions for Medicinal Cannabis products, however there are separate regulations that apply to interstate prescriptions.
24-hour clinical advice
The Drug and Alcohol Clinical Advisory Service (DACAS) offers professional advice to medical practitioners, pharmacists and other health professionals 24-hours.
Call DACAS on 1800 111 092.
Storage and transport
Health professionals producing or storing controlled Schedule 8 drugs read the Code of Practice for Schedule 8 Substances: Storage and Transport.
Schedule 8 code of practice
Document title | Index | Document Description |
---|---|---|
Code of Practice S8 Substances | ||
Code of Practice S8 Substances | ||
Code of Practice S8 Substances | ||
Code of Practice S8s - Volume 2 | Code of Practice S8 Substances | |
Appendix A - Notification of Supply of an Unrestricted S8 Substance | Appendix A | Notification Form |
Appendix B - Application for Authority to Prescribe a Restricted S8 Psychostimulant Medication | Appendix B | Application Form |
Appendix C - Application for Authority to Prescribe a Restricted S8 Substance for Addiction | Appendix C | Application Form |
Appendix D - Clinical Assessment for the Level of Supervised Dosing | Appendix D | Assessment Tool |
Appendix E1 - Application for Variation to Regular OSD Takeaway USD - Buprenorphine, Naloxone | Appendix E1 | Application Form |
Appendix E2 - Application for Variation to Regular OSD Takeaway USD - Methadone, Buprenorphine | Appendix E2 | Application Form |
Appendix F |
Publications
Forms |
---|
Agreement for patients prescribed general medications |
Opiate Pharmacotherapy Contract |
Drug Loss, Incident or Discrepancy Report Form PDF (159.1 KB) Drug Loss, Incident or Discrepancy Report Form DOCX (60.8 KB) |
Information sheets |
Requirements of Prescriptions for S8 Substances |
Information for Patients on S8 Medications DOCX (65.9 KB) |
Interstate S8 prescriptions state phone and fax: ACT Phone: (02) 6205 0998 Fax: (02) 6205 0997 NSW Main switch phone: (02) 9391 9944 Fax: (02) 9424 5860 Non-methadone phone: (02) 9424 5923 Fax: (02) 9424 5889 Methadone phone: (02) 9424 5921 Fax:(02) 9424 5885 Queensland Phone: (07) 3328 9890 Fax: (07) 3328 9821 South Australia Phone: 1300 652 584 Fax: 1300 658 447 Tasmania Phone: (03) 6166 0400 Fax: (03) 6233 3904 Victoria Phone: 1300 364 545 select #1 Fax: 1300 360 830 Western Australia Phone: (08) 9222 6883 Fax: (08) 9222 2463 NT Phone: (08) 8922 7341 Fax: (08) 8922 7200 |
Medical Practitioner Guide to Supplying Isotretinoin (47KB) |
The Scheduled Substances Clinical Advisory Committee (48KB) |
Patient Delivered Partner Therapy (47KB) |
Interstate Health Departments - S8 Drug Monitoring (44KB) |
Recommended reading on treatment of pain |
Opioid recommendations in general practice on the NSW Health website. |
National Prescribing Service (NPS) Medicine Wise website |
Patient guide to managing pain and opioid medicines Choosing Wisely Australia website |
Related information
Read more about scheduled substances in the Clinical Advisory Committee (CLAC).
For information on the following topics go to medicines and poisons safety:
- therapeutic goods recalls
- buying medicines online.
NTScript information for health professionals
Planned Upgrade
As part of ongoing performance and security upgrades, the NT Script login experience will change over the end of 2023.
The login page for NT Script is being upgraded to make it faster and more secure to login. This will change the ‘backend’ location of the page.
For most users, there will be no change. For users who have not logged in for over a month, their log in page will not load and they will be redirected to another page.
If you have saved the Practitioner Login page to your bookmarks, go to the NT Script website. You will need to update your bookmark.
If you try to access the log in page, you will receive a notification redirecting you to the updated page.
If you access NTScript through www.ntscript.nt.gov.au, you will not be affected.
You can contact the Medicines and Poisons team on 0889 227341 or ntscript@nt.gov.au.
Background
Prescription medicines are an important tool to manage the health of Territorians, however there is growing evidence nationally that particular medicines carry a high risk of dependence, misuse and over-use that is leading to increasing numbers of avoidable hospitalisations and death.
In 2018 State and Territory Health Ministers in conjunction with the Commonwealth Department of Health agreed to participate in a federated Real Time Prescription Monitoring solution based on the Victorian SafeScript model. Under this model all the states and territories will integrate with a national data exchange to enable real time prescription monitoring across the jurisdictions.
Prescription monitoring in the NT
The NT Chief Health Officer has undertaken monitoring of Schedule 8 (S8) Controlled Drugs since 1983, with pharmacies providing a weekly report of dispensed S8 prescriptions. The data was only available directly to regulators working for the Chief Health Officer, with a process for providing patient S8 histories to validated medical practitioners on email or telephone request. The NT Coroner recommended in 2017 that the NT Government implement real time prescription monitoring of Schedule 8 drugs.
The aim of a Real Time Prescription Monitoring (RTPM) system is to reduce the risks of dose escalation, dependence and overdose of select medicines by increasing the sharing of information between prescribers, pharmacists and regulators. RTPMs support clinical decision-making and encourage conversations between health professionals and their patients to identify and reduce the risk of medication related harm.
In July 2020, an agreement was signed between NT Health, the Commonwealth Department of Health and software provider FredIT for the NT to link to the Commonwealth’s federated RTPM and to develop an RTPM system for the NT.
The system is known as NTScript.
What information is collected?
Prescription details collected by NTScript include:
- name and address of the patient
- name and address of prescriber
- details of the practice where the prescriber is located
- date prescription is issued by the prescriber
- medicine details (name, brand, strength, quantity, instructions)
- details of pharmacy which dispenses the medicine
- date the medicine is dispensed
Which medicines are monitored?
“Monitored Substances” are those medicines that greatly increase risk to the patient due to likelihood of dose escalation, dependence, overdose, misuse and diversion.
NTScript replaces the monitoring system for Schedule 8 medicines in the NT that has been in operation since 2004.
S8 medicines include strong pain relievers such as morphine (e.g. MS Contin®, Kapanol®) and oxycodone (e.g. OxyContin®, Targin®), stimulants used to treat ADHD, narcolepsy and autosomal hypersomnolence (e.g. Ritalin®, Vyvanse®), and opioid substitution medicines methadone, buprenorphine and buprenorphine/naloxone.
Some Schedule 4 medicines have a recognised risk of overuse, overdose and death and as such have been recommended by experts to be included in RTPM systems. The additional monitored medicines includes:
- All benzodiazepines not in S8 – e.g. diazepam (Valium® , Antenex®)
- “Z-drugs” – zolpidem (e.g. Stilnox®) and zopiclone (e.g. Imovane®)
- quetiapine (e.g. Seroquel®)
- gabapentin (e.g. Neurontin®)
- Pregabalin (e..g Lyrica®)
- codeine combination products e.g. Panadeine Forte®
- tramadol
Supporting safe medicine use
NTScript does not determine if a medicine can or cannot be prescribed or supplied. If someone is receiving monitored medicines at high dose, high risk combinations or receiving monitored medicines from multiple providers they will be at a high risk of harm. Data in NTScript will be used to determine risk, coordinate care and support the safe and effective supply of medicines.
Identifying risks
The information in NTScript will help prescribers and pharmacists work with their patients to identify and manage risks. NTScript will generate Alerts within the software when criteria known to increase risk are present. Clinicians using conformant software will also see pop-up Notifications at the time of prescribing/dispensing to help identify where there is information in NTScript that should be considered.
Can someone opt out?
NTScript continues the mandatory monitoring in place since 1983 in the NT. It is not possible to opt out as the use and supply of these “monitored of substances” is a major public health and safety concern, to individual patients and to the general community.
How is privacy protected?
All data in NTScript is encrypted and stored in accordance with Commonwealth Department of Defence IT Standards. Access to NTScript is limited to prescribers, pharmacists and regulators. Users log in with multifactorial authentication which greatly reduces the risk of unauthorised access. All access to NTScript by any user is logged and privacy is protected under the NT Information Act 2002 and Commonwealth Privacy Act 1988.
How is patient consent managed?
The final decision to have a medicine prescribed or supplied is up to the patient in conjunction with their treating health professional. Health professionals should inform their patient when a medicine will be included in NTScript so that patients can choose not to receive the monitored medicine and alternative treatment or referral should then be provided instead.
Who can access the information?
- By law NT Script data can be accessed by certain classes of health practitioner registered with a national board. The health practitioners are prescribers (doctors, dentists, nurse practitioners, endorsed midwives and podiatrists) and pharmacists. These health practitioners first need to register for NTScript.
- An authorised user is allowed to access NTScript only to aid clinical decision making for providing direct care to a particular person.
- NT Department of Health staff who are responsible for the regulation of medicines on behalf of the Chief Health Officer will also have access as part of their duties.
- Patients can view information held against their details when they are discussing treatment options with their treating health practitioner, provided the health practitioner is registered for NTScript.
- Patients can also submit a Freedom of Information (FOI) request to the NT Department of Health.
Registration access and training
Eligible prescribers and pharmacists can register and access NTScript from the NTScript portal.
Contact details
Medicines and Poisons
NT Department of Health
Email: NTScript@nt.gov.au
Phone: (08) 8922 7341
Pharmacists
This page has information for pharmacists about prescription requirements, schedule 8 (S8) medicines and the pharmacist immunisations.
Pharmacists must familiarise themselves with the Medicines, Poisons and Therapeutic Goods Act 2012 and Regulations and the Code of Practice S8 Substances.
NT Script has been operational in the Northern Territory (NT) for some time and there is a legal requirement for every pharmacist to check when presented with a prescription for a schedule 8 or monitored medicine. Read further information about NT Script.
To get the S8 Code of Conduct see medical practitioners and schedule 8 medicines.
Unrestricted S8 substances
Prescribers must notify Medicines and Poisons of the supply of unrestricted S8 substances such as morphine and oxycodone if supply exceeds 8 weeks, or if other circumstances arise that are in the Code of Practice.
Prescribers may require authorisation if they choose to prescribe for more than an approved number of patients.
Compliance is the responsibility of the prescriber, and pharmacists are not expected to routinely monitor these matters as a part of dispensing.
However pharmacists email poisonscontrol@nt.gov.au if they have particular queries or concerns.
Restricted S8 substances
These categories of S8 substances have the following supply restrictions applied to them.
Stimulants
Stimulants include dexamfetamine, lisdexamfetamine and methylphenidate.
General medical practitioners and nurse practitioners can co-prescribe in conjunction with a specialist paediatrician, psychiatrist, neurologist, physician or registrar in training in one of these disciplines.
Prescribers are required to obtain authorisation before prescribing these substances.
Pharmacists are not required to check whether a prescriber has obtained authorisation, however they may contact Medicines and Poisons with queries or concerns.
Opioid Substitution Treatment (OST)
Methadone, buprenorphine and buprenorphine/naloxone.
Eligible health practitioners who wish to prescribe OST must:
- be accredited by the CHO and
- must also apply and receive authorisation for each patient they wish to prescribe the restricted S8 OST substance for.
More information for prescribers about accreditation and training to become an OST prescriber, contact the local Alcohol and Other Drugs Service:
Top End Alcohol and other Drug Services
Building 9, Royal Darwin Hospital
Phone: 08 8922 8399
Alcohol and other Drugs Services Central Australia (ADSCA)
The Gap NT 0870
Phone: 08 8951 7580
Medicines and Poisons can provide information on whether prescribers are accredited.
Prescription requirements
The S8 Code has these requirements for prescriptions of controlled drugs:
- prescriptions for unrestricted S8 substances such as morphine are valid for 6 months, with dispensing of one month’s supply at any one time
- prescriptions for restricted S8 psycho-stimulants (dexamphetamine, lisdexamfetamine and methylphenidate) are valid for 6 months
- prescriptions for restricted S8 substances buprenorphine, buprenorphine/naloxone and methadone 5mg/mL are valid for 3 months - they must be dispensed within 3 days of the date of issue or the start date (if different)
- according to the S8 Code the following items must be written on all S8 prescriptions, in addition to usual requirements for prescriptions:
- the date of birth of the patient
- the type of preparation i.e. liquid or sublingual tablets
- doses in words and numbers for buprenorphine, buprenorphine/naloxone and methadone
- quantities in words and numbers for unrestricted S8 substances and psycho-stimulant medication, unless issued by a conformant electronic prescribing system
- a prescription must be written in ink, not in pencil or another easily erasable material
- if there are any changes to the details, the initials of the person who issued the prescription and the date the change was made must appear beside each change
- prescribers must sign prescriptions in their handwriting unless they are using an electronic prescribing system
- prescribers of buprenorphine, buprenorphine/naloxone and methadone liquid, also need to include the name of the dispensing pharmacy as well as a detailed dosage regimen and any takeaway privileges.
Interstate prescriptions
Dispensing from prescriptions written by prescribers based interstate is permitted for schedule 4 medicines.
Prescriptions for unrestricted schedule 8 medicines written by interstate prescribers can be dispensed in the NT in line with Regulation 7A of the regulations which outlines that a pharmacist must verify:
- the validity of the prescription - the prescription must meet all legal requirements that apply to prescriptions written in the NT
- the identify of the person presenting the prescription.
Prescriptions for restricted schedule 8 medicines that are psychostimulants (methylphenidate, dexamphetamine, lisdexamphetamine) medicines written by interstate prescribers can be dispensed in the NT where the prescriber would normally be endorsed to initiate treatment in the Territory. This includes:
- paediatricians
- psychiatrists
- neurologists
- physicians.
The prescription will often include the prescriber’s qualifications. Otherwise prescriber qualifications can be checked on the AHPRA website.
National Poisons Standard
Publications
Related information
Read more about scheduled substances on Clinical Advisory Committee (CLAC).
For information on the following topics, go to the Northern Territory Government website:
- therapeutic goods recalls
- buying medicines online.
Pharmacist vaccinations
Pharmacists have been vaccinating in the NT since 2015.
On 8 December 2023 the NT Chief Health Officer approved a new Scheduled Substance Treatment Protocol (SSTP) for pharmacist vaccination which applies to all pharmacists in the NT.
Pharmacists are now enabled to administer a broader range of vaccines in the NT without a prescription:
- For people aged 5 years and over
- For a defined range of vaccines
- Where they have undergone immunisation specific training
- Where the immunisation is in accordance with public health programs (National Immunisation Program, NT Immunisation Schedules)
The full range of vaccines and indications is listed on the SSTP PDF (849.6 KB).
At this time, the SSTP does not enable travel vaccines or occupational vaccination where this does not align with the NIP and NT Schedules.
Using the NIP and NT Schedules
The National Immunisation Program (NIP) Schedule is a series of immunisations given at specific times throughout a persons life.
The National Immunisation Program Vaccinations in Pharmacy (NIPVIP) Program is a commonwealth initiative enabled through NT health and is effective from 1 January 2024. The NIPVIP enables participating pharmacists to receive vaccines at no cost and increases access for eligible (under the NIP) people to access FREE NIP vaccines in a community pharmacy with no out of pockets costs.
This range of conditions and people are outlined on the National Immunisation Program Schedule
Pharmacists may vaccinate people in line with the NIP schedule, regardless if they are doing so under NIP program rules and funding models or if the patient is choosing to pay privately.
The NT Health Immunisation Schedules outline the priority vaccinations to meet the unique needs of the NT. This is based on the NIP schedule with minor amendments and increased eligibility for some Indigenous patients.
Pharmacists may vaccinate people in line with the NT Schedule or National Immunisation Program schedule however payment under the NIPVIP is based on the NP vaccines in a pharmacy setting for individuals aged 5 years and over.
Pharmacists vaccinating at pharmacy premises
Pharmacy premises must meet the Pharmacy Premises Standard PS5
Pharmacists vaccinating at other locations
The SSTP outlines the minimum requirements of a location where pharmacists will be administering medicines. This includes critical concepts such as anaphylaxis management, cleanliness, waste disposal and cold chain management.
Intern Pharmacists
Pharmacists with provisional registration (intern pharmacists) are able to administer vaccines provided they adhere to the requirements as outlined in the SSTP and are under the supervision of a pharmacist who is qualified to vaccinate.
Further Information
If you are a pharmacy owner, manager of a pharmacy or pharmacist and you are interested in providing an immunisation service please contact:
The Registrar, Pharmacy Premises Committee
PPCRegistrar.DoH@nt.gov.au
Or
Medicines and Poisons
Poisonscontrol@nt.gov.au
Therapeutic medicines containing cannabinoids (medicinal cannabis)
The Australian Government Department of Health regulates therapeutic medicines containing cannabis through the Therapeutic Goods Administration and for importation or production, the Office of Drug Control.
Access is restricted to patients where there is evidence to support its therapeutic use.
For further information read the:
- Therapeutic Goods Administration website or phone 1800 020 653
- Office of Drug Control or phone (08) 6232 8740
Patients living in the Northern Territory
Medical cannabis pharmaceuticals are prescription medicines, so access for each patient starts with assessment by a medical practitioner. General practitioners (GPs) may refer a patient to a specialist to obtain further advice and support before deciding to prescribe a medicinal cannabis pharmaceutical.
The Northern Territory does not apply any specific regulation to the prescribing and supply of medicinal cannabis pharmaceuticals.
However a doctor must obtain approval from the Therapeutic Goods Administration under the Special Access or Authorised Prescriber Schemes (or for a Clinical Trial) before issuing a prescription or supplying a medicinal cannabis pharmaceutical which is not on the Australian Register of Therapeutic Goods (ARTG).
Some medicinal cannabis pharmaceuticals are classified as Schedule 8 medicines depending on their THC content. Schedule 8 medicines have extra requirements in the NT including reporting to the monitored medicines database, prescription contents and supply and storage requirements.
For further information read the:
- Access to Medicinal Cannabis/CBD Oil in the NT Information Sheet
- Therapeutic Goods Administration website’s Access to medicinal cannabis product page or phone 1800 020 653
Northern Territory hospital formulary
The NT Hospital formulary is a list of core medicines which are approved for use within NT public hospitals and health services. Through a Territory-wide approach to the availability of medicines, NT Department of Health (DoH) aims to optimise the quality use of medicines, improve and promote equity of access to medicines and increase the cost-effectiveness of medicine use across the NT.
Download the NT Hospital formulary DOCX (434.0 KB)
For any queries related to NT Hospital Formulary, email NTDTC.DoH@nt.gov.au.
Search medicines from the list
Formulary listing key:
- Y – Listed on NT Hospital Formulary and not restricted
- S – Highly Specialised Drugs Program (Section 100)
- R – Listed on NT Hospital Formulary with restrictions
Drug | Dose form | Strength | Formulary Listing | Notes |
---|---|---|---|---|
ABACAVIR | Tablet | 300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ABACAVIR & LAMIVUDINE | Tablet | 600/300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ABIRATERONE | Tablet | 250mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
ACAMPROSATE | Tablet | 333mg | R | Restricted to Addiction medicine prescribers |
ACETAZOLAMIDE | Injection | 500mg | Y | |
ACETAZOLAMIDE | Tablet | 250mg | Y | |
ACETIC ACID | Solution | 0.25% & 5% | Y | |
ACETONE | Liquid | Y | ||
ACETYLCHOLINE | Intraocular Irrigation | 1% (2mg/2mL) | Y | |
ACETYLCYSTEINE | Injection | 2g/10mL | Y | |
ACETYLCYSTEINE | Nebulised vial | 800mg/4mL | Y | |
ACICLOVIR | Injection | 250mg | Y | |
ACICLOVIR | Tablet | 200mg & 800mg | Y | |
ACICLOVIR | Ointment | 3% | Y | |
ACICLOVIR COLD SORE | Cream | 5% | Y | |
ACTIVATED CHARCOAL | Oral Liquid | 0.2g/mL | Y | |
ADALIMUMAB | Injection | 40mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ADEFOVIR DIPIVOXIL | Tablet | 10mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ADENOSINE | Injection | 6mg/2mL | Y | |
ADRENALINE (EPINEPHRINE) | Injection | 1 in 1000 & 1 in 10 000 | Y | |
ADRENALINE (EPINEPHRINE) | Min-I-Jet | 1 in 1000 | Y | |
ADRENALINE (EPINEPHRINE) | Auto-injector | 300 mcg & 150 mcg | R | EPI-PEN® AND EPI-PEN® JUNIOR Restricted to after-hours use only by the Emergency Department. |
ALBENDAZOLE | Tablet | 200mg | Y | |
ALCOHOL | Injection | 100% | Y | |
ALCOHOL | Solution | 70% untinted, 95% untinted, absolute | Y | |
ALCOHOL STERILE SPRAY | Spray | 70% | Y | |
ALENDRONATE | Tablet | 70mg | Y | |
ALFENTANIL | Injection | 1mg/2mL | Y | |
ALLOPURINOL | Tablet | 100mg & 300mg | Y | |
ALPROSTADIL | Injection | 500 mcg | Y | |
ALTEPLASE | Syringe Vial | 2mg/2mL | Y | Cathflo® to be restricted for supply to services where logistics of delivering and storing the frozen pre-filled syringe is not available. Note: There is a current global shortage issue with alteplase. There is a requirement to conserve alteplase stock for life-saving indications only. |
ALTEPLASE | Injection | 10mg | R | Restricted for use by respiratory specialists/advanced trainees with experience in its use for empyema management Note: There is a current global shortage issue with alteplase. There is a requirement to conserve alteplase stock for life-saving indications only. |
ALTEPLASE | Injection | 50mg | R | Restricted to Cardiology and ICU only Restricted to ED for stroke thrombolysis under direction of the Neurologist. Note: There is a current global shortage issue with alteplase. There is a requirement to conserve alteplase stock for life-saving indications only. |
AMIES MEDIUM SWABS | Single Swabs | Y | ||
AMIKACIN | Injection | 500mg/2mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
AMINO ACID AND CARBOHYDRATE SUPPLEMENT (HEPATICAL®) | Sachet | 100grams | Y | |
AMINO ACID LONG CHAIN POLYUNSATURATED FATTY ACIDS | Powder | R | Restricted to PBS indications. | |
AMINO ACIDS 7% GLUCOSE | Solution | 7% | Y | |
AMINOPHYLLINE | Injection | 250mg | Y | |
AMIODARONE | Injection | 150mg | Y | |
AMIODARONE | Tablet | 100mg & 200mg | Y | |
AMISULPRIDE | Tablet | 100mg, 200mg & 400mg | R | Restricted to Mental Health |
AMITRIPTYLINE | Tablet | 10mg, 25mg & 50mg | Y | |
AMLODIPINE | Tablet | 5mg & 10mg | Y | |
AMOXICILLIN | Suspension | 250mg/5mL | Y | |
AMOXICILLIN | Capsule/ Tablet | 250mg, 500mg & 1000mg | Y | |
AMOXICILLIN, CLARITHROMYCIN & ESOMEPRAZOLE (Nexium HP7 Triple Therapy Pack®) | Tablet | 500mg/ 250mg/ 20mg | Y | |
AMOXICILLIN/ CLAVULANIC ACID | Injection | 1g+200mg, 500mg+100mg, 2g+200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
AMOXICILLIN/ CLAVULANIC ACID (Augmentin Duo®) | Tablet | 500/125mg & 875/125mg | Y | |
AMOXICILLIN/ CLAVULANIC ACID (Augmentin Duo®) | Suspension | 400/57mg /5mL | Y | |
AMPHOTERICIN | Lozenges | 10mg | Y | |
AMPHOTERICIN LIPOSOMAL | Injection | 50mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
AMPICILLIN | Injection | 500mg & 1g | Y | |
ANAKINRA | Injection | 100mg | R | Restricted to ICU Physicians as per use in REMAP CAP clinical trials only |
ANASTROZOLE | Tablet | 1mg | R | Restricted to Oncology and Haematology only |
ANIDULAFUNGIN | Injection | 100mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
ANTIVENOM BOX JELLYFISH | Injection | 20 000 units | Y | |
ANTIVENOM-BLACK SNAKE | Injection | 18 000 units | Y | |
ANTIVENOM-BROWN SNAKE | Injection | 1 000 units | Y | |
ANTIVENOM-DEATH ADDER | Injection | 6 000 units | Y | |
ANTIVENOM-POLYVALENT SNAKE | Injection | 40 000 units | Y | |
ANTIVENOM-RED BACK SPIDER | Injection | 500 units | Y | |
ANTIVENOM-SEA SNAKE | Injection | 1000 units | Y | |
ANTIVENOM-STONE FISH | Injection | 2000 units | Y | |
ANTIVENOM-TAIPAN SNAKE | Injection | 12 000 units | Y | |
APIXABAN | Tablet | 2.5mg & 5mg | R | Restricted to PBS indications. |
APRACLONIDINE | Eye drop | 0.50% (5mg/mL) | Y | |
AQUEOUS CREAM | Cream | Y | ||
ARGIPRESSIN (VASOPRESSIN) | Injection | 20units | R | Restricted to ICU |
ARIPIPRAZOLE | Tablet | 10mg, 15mg, 20mg & 30mg | R | Restricted to Mental Health for the treatment of schizophrenia. |
ARIPIPRAZOLE (Abilify Maintena®) | Depot Injection | 300mg & 400mg | R | Restricted to Mental Health for the treatment of schizophrenia. |
ARTEMETHER & LUMEFANTRINE (Riamet®) | Tablet | 20mg/120mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
ARTESUNATE | Injection | 60mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ASCORBIC ACID | Injection | 15g/100mL | R | REMAP CAP Trial as prescribed by the ICU consultants. |
ASCORBIC ACID | Tablet | 500mg | Y | |
ASPIRIN | Dispersible tablets | 300mg | Y | |
ASPIRIN | Tablet | 100mg | Y | |
ATAZANAVIR | Capsule | 200mg & 300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ATAZANAVIR & COBICISTAT | Tablet | 300mg+150mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ATENOLOL | Tablet | 50mg | Y | |
ATENOLOL | Liquid | 50mg/10mL | Y | |
ATORVASTATIN | Tablet | 10mg, 20mg, 40mg & 80mg | Y | |
ATOVAQUONE & PROGUANIL | Tablet | 250mg/100mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
ATRACURIUM | Injection | 25mg | Y | |
ATROPINE SULFATE | eye drop & Minims | 1% | Y | |
ATROPINE SULFATE | Injection | 600mcg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
AZACITIDINE | Injection | 100mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
AZATHIOPRINE | Tablet | 25mg & 50mg | Y | |
AZITHROMYCIN | Injection | 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
AZITHROMYCIN | Suspension | 200mg/ 5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for bronchiectasis in paediatric patients. |
AZITHROMYCIN | Tablet | 500mg & 600mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for bronchiectasis in paediatric patients and for susceptible infections not listed on the PBS approved by Infectious Disease/Tuberculosis clinic only. |
AZTREONAM | Injection | 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
BACLOFEN | Intrathecal Injection | 10mg/5mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
BACLOFEN | Tablet | 10mg & 25mg | Y | |
BALANCED SALT | Solution | Y | ||
BATH WASH (Q.V. SOAP FREE KIDS WASH®) | Wash | Y | ||
MYCOBACTERIUM BOVIS (BACILLUS CALMETTE AND GUERIN (BCG) STRAIN BLADDER INSTALLATION (Immucyst®) | Syringe | R | Restricted to Urologist | |
BCG VACCINE | Injection | Y | ||
BECLOMETHASONE | Nasal Spray | 50mcg | Y | |
BECLOMETASONE/FORMOTEROL/ GLYCOPYRRONIUM (Trimbow®) | Inhaler | 100mcg/6mcg/ 10mcg | R | Restricted to PBS indications. |
BENDAMUSTINE | Injection | 25mg & 100mg | R | Restricted to Haematology/Oncology. |
BENZATHINE PENICILLIN (LA Bicillin®) | Injection | 1,200,000 Units (900mg)/2.3mL, 600,000 Units (517mg)/1.17mL | Y | |
BENZOIN COMPOUND (Friars’ Balsam Tincture) | Tincture | Y | ||
BENZTROPINE | Injection | 2mg | Y | |
BENZTROPINE | Tablet | 2mg | Y | |
BENZYDAMINE (Difflam®) | Liquid | 22.5mg/15mL | Y | |
BENZYDAMINE/ LIDOCAINE (LIGNOCAINE)/DICHLOROBENZYL ALCOHOL (Difflam Plus ®) | Lozenges | 3mg/4mg/1.2mg | Y | |
BENZYL BENZOATE | Solution | 25% | Y | |
BENZYLPENICILLIN | Injection | 600mg, 1.2g & 3g | Y | |
BENZYLPENICILLIN (PENICILLIN G) | Infusor | 3.6g/6g | Y | |
BETAHISTINE | Tablet | 16mg | Y | |
BETAMETHASONE (Celestone Chronodose®) | Injection | 5.7mg/mL | Y | |
BETAMETHASONE DIPROPIONATE | Ointment/ Cream | 0.05% | Y | |
BETAMETHASONE DIPROPIONATE/ CALCIPOTRIOL | Ointment | 0.05%/0.005% | Y | |
BETAMETHASONE VALERATE | Cream | 0.02% | Y | |
BETAXOLOL | Eye drops | 0.25% & 0.5% | Y | |
BEVACIZUMAB | Intravitreal Injection | R | Restricted to eye clinic - for Ophthalmology specialist use only. Avastin® brand only. Not to substitute with biosimilars. For SAS Avastin®, please complete appropriate SAS form (Category B) which can be located on the TGA website. SAS form is not required for TGA-approved Authorised Prescribers. | |
BEVACIZUMAB | Injection | 100mg/4mL, 400mg/16mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
BICALUTAMIDE | Tablet | 50mg | R | Restricted to Haematology and Oncology |
BICTEGRAVIR, EMTRICITABINE & TENOFOVIR ALAFENAMIDE | Tablet | 50mg+200mg+25mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
BIFIDOBACTERIA BIFIDUM & LACTOBACILLUS ACIDOPHILIS (Infloran®) | Capsule | 1 x 109 1 x 109 | R | Restricted to Special Care Nursery and Neonatal Intensive Care Unit. |
BIFIDOBACTERIUM INFANTIS, BIFIDOBACTERIUM BIFIDUM, LACTOBACILLUS ACIDOPHILUS (Labinic Paediatric Drops ®) | Drops | 1.5 billion CFU/0.16mL | R | Restricted to Special Care Nursery and Neonatal Intensive Care Unit during the period that Infloran® is unavailable. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
BISACODYL | Tablet | 5 mg | Y | |
BISACODYL | Enema | 10mg/5mL | Y | |
BISACODYL | Suppository | 10mg | Y | |
BISMUTH & IODOFORM GAUZE | GAUZE | Y | ||
BISOPROLOL | Tablet | 2.5mg, 5mg & 10mg | Y | |
BIVALIRUDIN | Injection | 250mg | R | Restricted to use in RDH ICU by ICU specialists only – please refer to RDH ICU: Medical Management of suspected Heparin Induced Thrombocytopaenia with or without Thrombosis (HIT/HITTS) guideline |
BLEOMYCIN | Injection | 15,000 international units | R | Restricted to Haematology and Oncology for PBS listed indications. |
BNT162b2 [mRNA] COVID-19 VACCINE (Comirnaty®) | Injection | R | As per eligibility criteria outlined in the Australian Government Immunisation Implementation plan January 2021 | |
BONE CEMENT with TOBRAMYCIN | Y | |||
BORTEZOMIB | Injection | 1mg & 3.5mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
BOSENTAN | Tablet | 62.5mg & 125mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Restricted to patients <18 years old. Macitentan is first line for adults. |
BOTULINUM A TOXIN | Injection | 100 units & 500 units | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Restricted to surgical division/gastroenterology for treatment of anal fissure repair for patients who have failed conservative/first-line medical measures (100 unit injection only). Restricted to Maxillofacial surgeons for patients ≥12 years of age for the following indications (100 unit injection only): * For salivary leaks/collections following procedures on or through (access to mandibular condyle) the parotid gland/parotidectomy |
BRANCHED CHAIN AMINO ACIDS POWDER | Sachet | Y | ||
BREXPIPRAZOLE | Tablet | 1mg, 2mg, 3mg & 4mg | Y | |
BRIMONIDINE | Eye drops | 0.20% | Y | |
BRINZOLAMIDE | Eye drops | 1% | Y | |
BROMHEXINE | Elixir Tablet | 4mg/5mL 8mg | Y | |
BROMOCRIPTINE | Tablet | 2.5mg | Y | |
BUDESONIDE | Nasal Spray | 64mcg | Y | |
BUDESONIDE | Capsule and Tablet | 3mg & 9mg | R | Blanket approval for inpatient and outpatient supply. Restricted to gastroenterologists for the; Induction therapy for extensive ulcerative colitis if no response to sulfasalazine or mesalazine, or intolerance to either drug – 8 weeks therapy Treatment of microscopic colitis – ongoing Contraindications to prednisolone for the treatment of autoimmune gastrointestinal diseases (e.g. refractory coeliac disease, eosinophilic esophagitis, autoimmune hepatitis, inflammatory bowel disease) – ongoing |
BUDESONIDE | Turbuhaler | 100mcg, 200mcg & 400mcg | Y | |
BUDESONIDE | Respule | 500mcg/2mL & 1mg/2mL | Y | |
BUDESONIDE/ FORMOTEROL (EFORMETEROL) (Symbicort®) | Rapihaler | 50/3mcg & 100/3mcg & 200/6mcg | Y | |
BUPIVACAINE | Infusion | 0.125%, 0.25% & 0.5% | Y | |
BUPIVACAINE & ADRENALINE | Injection | 0.25%/ 1:400,000 | Y | |
BUPIVACAINE & FENTANYL | Injection | 0.125%/2mcg/ mL | Y | |
BUPIVACAINE & FENTANYL | Injection | 0.0625%/2.5mcg/mL | Y | *For use as labour epidural |
BUPIVACAINE & GLUCOSE | Injection | 0.5% | R | Operating Theatre |
BUPRENORPHINE | Sublingual Tablet | 400mcg, 2mg & 8mg | R | Restricted to Addiction medicine prescribers |
BUPRENORPHINE | Sublingual Tablet | 200mcg | R | Restricted to Acute Pain Specialists for patients who are: Inpatients only and The patient is unable to absorb via the oral route and A discharge plan for analgesia has been considered or It’s a continuation of regular mediation |
BUPRENORPHINE (Norspan®) | Patch | 5mg (5 mcg/hr), 10mg (10 mcg/hr) & 20mg (20 mcg/hr) | R | Chronic severe disabling pain not responding to non-narcotic analgesics. |
BUPRENORPHINE & NALOXONE | Sublingual Film | 2mg/0.5mg & 8mg/2mg | R | Restricted to Addiction medicine prescribers |
BUPRENORPHINE (Buvidal®) | Weekly Depot Injection | 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL & 32 mg/0.64 mL | R | Restricted to Addiction medicine prescribers |
BUPRENORPHINE (Buvidal®) | Monthly Depot Injection | 64 mg/0.18 mL, 96 mg/0.27 mL, 128 mg/0.36 mL & 160mg/0.45mL | R | Restricted to Addiction medicine prescribers |
BUPRENORPHINE (Sublocade®) | Monthly Depot Injection | 100mg/0.5mL & 300mg/1.5mL | R | Restricted to Addiction medicine prescribers |
CABAZITAXEL | Injection | 60mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
CABERGOLINE | Tablet | 1mg | Y | |
CABOTEGRAVIR | Tablet | 30mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
CABOTEGRAVIR & RILPIRIVINE (combination pack) | Injection | 600mg/3mL & 900mg/3mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
CAFFEINE (BASE) | Oral Solution | 10mg/mL (50mL) | Y | |
CAFFEINE (BASE) | Injection | 20mg/2mL | Y | |
CALAMINE | Lotion | 15% | Y | |
CALCITRIOL | Capsule | 0.25mcg | Y | |
CALCIUM & MAGNESIUM CHLORIDE | Haemofiltration infusion | R | To ICU only | |
CALCIUM CARBONATE | Tablet | 1.25g | Y | |
CALCIUM CARBONATE/COLECALCIFEROL (CHOLECALCIFEROL) | Tablet | 1.5g/12.5mcg | R | Restricted to Haematology and Oncology. |
CALCIUM CHLORIDE | Injection | 10% | Y | |
CALCIUM DISODIUM EDETATE | Injection | 500mg/10mL | R | Stock held by RDH Emergency Department for treatment of severe lead poisoning. |
CALCIUM FOLINATE | Injection | 50mg | Y | |
CALCIUM FOLINATE | Tablet | 15mg | Y | |
CALCIUM GLUCONATE | Injection | 931mg/10mL (2.2 mmol/10mL elemental calcium); also formerly known as Calcium Gluconate 10% | Y | |
CALCIUM GLUCONATE | Gel | 2.50% | Y | |
CANDESARTAN | Tablet | 4mg & 16mg | Y | |
CAPECITABINE | Tablet | 150mg & 500mg | R | Restricted to Haematology and Oncology for PBS listed indications AND for EOX protocol for upper GI. |
CAPSAICIN | Cream | 0.075% | Y | For acute treatment of cannabinoid hyperemesis syndrome. |
CAPTOPRIL | Solution | 25mg/5mL | Y | |
CARBAMAZEPINE | Modified release Tablets | 200mg & 400mg | Y | |
CARBAMAZEPINE | Tablet | 200mg | Y | |
CARBAMAZEPINE | Suspension | 100mg/5mL | Y | |
CARBIMAZOLE | Tablet | 5mg | Y | |
CARBETOCIN | Injection | 100mcg/mL | R | Restricted to Obstetrician or Anaesthetist in attendance for prevention of uterine atony and postpartum haemorrhage following the delivery of an infant by elective caesarean section under epidural or spinal anaesthesia |
CARBOPLATIN | Injection | 150mg/5mL, 450mg/45mL & 50mg/5mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
CARBOPROST | Injection | 250mcg/mL | Y | |
CARMELLOSE (Cellufresh®) | Eye drop | 0.50% | Y | |
CARNITINE | Solution | 1g/10mL | Y | |
CARVEDILOL | Tablet | 3.125mg, 6.25mg, 12.5mg & 25mg | Y | |
CASPOFUNGIN | Injection | 50mg & 70mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFALEXIN MONOHYDRATE | Capsules | 250mg & 500mg | Y | |
CEFALEXIN MONOHYDRATE | Suspension | 250mg/5mL | Y | |
CEFAZOLIN | Eye drop | 5% | R | Restricted to eye clinic (Manufactured at RDH). Blanket outpatient approval for treatment or prevention of ophthalmic infections. |
CEFAZOLIN | Injection | 1g | Y | |
CEFAZOLIN | Infusor | Y | ||
CEFEPIME | Injection | 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFIDEROCOL | Injection | 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Prescribing to be restricted to Infectious disease (IFD) in susceptible infections for patients in whom other alternatives are inappropriate |
CEFOTAXIME | Injection | 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFOXITIN | Infusor | 1g & 12g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFTAROLINE | Injection | 600mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFTAZIDIME | Injection | 1g & 2g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFTAZIDIME | 24 hour Infusor | 2g, 3g, 4g, 5g & 6g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFTAZIDIME/AVIBACTAM | Injection | 2g/0.5g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Prescribing to be restricted to Infectious disease (IFD) in susceptible infections for patients in whom other alternatives are inappropriate |
CEFTRIAXONE | Infusor | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT | |
CEFTRIAXONE | Injection | 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFUROXIME | Tablet | 250mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CEFUROXIME | Suspension | 125mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CELECOXIB | Capsule | 100mg & 200mg | Y | |
CETIRIZINE | Tablet | 10mg | R | For patients who fail to respond to loratadine. Restricted to dermatology and immunology. |
CETOMACROGOL | Cream | 100g | Y | |
CETUXIMAB | Injection | 100mg/20mL & 500mg/100mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
CHLORAL HYDRATE | Solution | 1g/10mL | Y | |
CHLORAMBUCIL | Tablet | 2mg | Y | Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
CHLORAMPHENICOL | Injection | 1g | R | Restricted to ICU and IFD only. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
CHLORAMPHENICOL (Chlorsig®) | Eye ointment | 1% | Y | |
CHLORAMPHENICOL (Chlorsig®) | Eye Drops | 0.50% | Y | |
CHLORHEXIDINE | Obstetric cream | 1% | Y | |
CHLORHEXIDINE | Mouth wash | 0.20% | Y | |
CHLORHEXIDINE 3mg/PHENYLEPHRINE 2.5mg | Nasal Ointment | 0.3%/0.25% | Y | |
CHLORHEXIDINE IN ALCOHOL 70% | Solution | 0.50% | Y | |
CHLORHEXIDINE SCRUB | Medisponge | Y | ||
CHLORHEXIDINE/ CETRIMIDE | Irrigation | 0.015/0.15% | Y | |
CHLORHEXIDINE/ CETRIMIDE | Solution | 0.015/0.15% | Y | |
CHLORHEXIDINE/ CETRIMIDE | Cream | 0.1%/0.5% | Y | |
CHLORPROMAZINE | Injection | 50mg/2mL | Y | |
CHLORPROMAZINE | Tablet | 10mg, 25mg & 100mg | Y | |
CHLORPROMAZINE | Syrup | 25mg/5mL | Y | |
CHOLINE SALICYLATE/CETALKONIUM CHLORIDE/MENTHOL (Sedagel®) | Dental Gel | 8.7%/0.01%/0.057% | Y | |
CICLOSPORIN | Injection | 50mg/mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
CICLOSPORIN | Capsule | 10mg, 25mg, 50mg & 100mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
CINACALCET | Tablet | 30mg, 60mg & 90mg | R | Restricted to nephrologists for patients who meet the PBS criteria |
CINCHOCAINE & HYDROCORTISONE (Proctosedyl®) | Suppositories | 5mg/5mg | Y | |
CINCHOCAINE & HYDROCORTISONE (Proctosedyl®) | Ointment | 0.5%/0.5% | Y | |
CINCHOCAINE & ZINC OXIDE (Rectinol®) | Ointment | 0.5%/20% | Y | |
CIPROFLOXACIN | Ear Drops | 0.30% | Y | |
CIPROFLOXACIN | Tablet | 250mg, 500mg & 750mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
CIPROFLOXACIN | Injection | 200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CIPROFLOXACIN/ HYDROCORTISONE (CIPROFLOXACIN CO®) | Ear Drops | 0.2%/1% | Y | |
CISPLATIN | Injection | 100mg/100mL & 50mg/50mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
CITALOPRAM | Tablet | 20mg | Y | |
CLADRIBINE | Injection | 10mg/10mL & 10mg/5mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
CLARITHROMYCIN | Tablet | 250mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
CLINDAMYCIN | Capsule | 150mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CLINDAMYCIN | Solution | 75mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Use restricted to discharge and outpatients only. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
CLINDAMYCIN | Injection | 600mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
CLOFAZAMINE/ DAPSONE/ RIFAMPICIN (LEPROSY PACK) | Capsules & Tablets | 300mg/100mg/ 100mg | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
CLONAZEPAM | Injection | 1mg | Y | Blanket outpatient approval for Palliative care patients. |
CLONAZEPAM | Solution | 2.5mg/mL | Y | Blanket outpatient approval for Palliative care patients. |
CLONAZEPAM | Tablet | 500mcg & 2mg | Y | Blanket outpatient approval for Palliative care patients. |
CLONIDINE | Injection | 150mcg/1mL | Y | |
CLONIDINE | Tablet | 100mcg & 150mcg | Y | |
CLOPIDOGREL | Tablet | 75mg | Y | |
CLOTRIMAZOLE | Pessary | 500mg | Y | |
CLOTRIMAZOLE | Vaginal Cream | 1% | Y | |
CLOTRIMAZOLE | Cream | 1% | Y | |
CLOVE OIL BP | Oil | 10mL | Y | |
CLOZAPINE | Tablet | 25mg, 50mg, 100mg & 200mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
COAL TAR | Solution | 200mL | Y | |
COBICISTAT, ELVITEGRAVIR, EMTRICITABINE & TENOFOVIR ALAFENAMIDE | Tablet | 150mg+150mg+ 200mg+10mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
COCAINE | Solution | 10% | Y | |
CODEINE PHOSPHATE | Tablet | 30mg | Y | |
COLCHICINE | Tablet | 500mcg | Y | |
COLECALCIFEROL | Capsule | 1000 units | Y | |
COLECALCIFEROL | Oral Solution | 5000 units / mL | Y | |
COLESTYRAMINE LIGHT | Sachets | 4g | Y | |
Colistimethate Sodium (Colistin) | Injection | 150mg/2ml | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
COLLOIDAL OATMEAL (DermaVeen®) | Lotion | 20mg/g | R | Restricted to burns unit & wound clinic |
COMBINATION ANTACIDS | Suspension Tablet | Y | ||
CONJUGATED ESTROGENS | Tablet | 300microg & 625microg | Y | |
CORTISONE ACETATE | Tablet | 5mg & 25mg | Y | |
COVID MEDICINES | - | - | R | Blanket approval for all medicines listed in the National Living COVID Guidelines. Blanket approval for prescribers to use Clinical Excellence Commission (CEC) resources available at: COVID-19 Resources - NSW Therapeutic Advisory Group (nswtag.org.au) and Medication Safety Updates - Clinical Excellence Commission (nsw.gov.au) |
CROTAMITON | Cream | 10% | Y | |
CYCLIZINE | Injection | 50mg/mL | R | Restricted to Anaesthetics and Palliative Care for the treatment of postoperative nausea and vomiting, and nausea and vomiting in the palliative care setting. Blanket outpatient approval for prevention of nausea and vomiting in Palliative Care patients. |
CYCLOPENTOLATE | eye drop & Minims | 1% | Y | |
CYCLOPENTOLATE | Minims | 0.50% | Y | |
CYCLOPHOSPHAMIDE | Infusor | Y | ||
CYCLOPHOSPHAMIDE | Injection | 500mg, 1gram & 2gram | Y | |
CYCLOPHOSPHAMIDE | Tablet | 50mg | Y | Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
CYPROTERONE | Tablet | 50mg | Y | |
CYTARABINE | Injection | 100mg/5mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
DABRAFENIB | Capsules | 50mg, 75mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
DACARBAZINE | Infusion | R | Restricted to Haematology and Oncology for Metastatic Melanoma and Hodgkin’s Lymphoma. | |
DACTINOMYCIN | Injection | R | Restricted to Haematology and Oncology for Low Risk Gestational Trophoblastic Disease. | |
DANTROLENE | Injection | 20mg | Y | |
DANTROLENE | Capsules | 25mg & 50mg | Y | |
DAPAGLIFLOZIN | TABLET | 10mg | Y | |
DAPSONE | Tablet | 100mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
DAPTOMYCIN | Injection | 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
DARBEPOETIN ALFA | Injection | 10mcg, 20mcg, 30mcg, 40mcg, 60mcg, 80mcg, 100mcg & 150mcg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DARUNAVIR | Tablet | 600mg & 800mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DARUNAVIR & COBICISTAT | Tablet | 800mg+150mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DARUNAVIR, COBICISTAT, EMTRICITABINE & TENOFOVIR ALAFENAMIDE | Tablet | 800mg+150mg+ 200mg+10mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DAUNORUBICIN MINIBAG | Injection | R | Restricted to Haematology and Oncology for Acute Myeloid Leukaemia. | |
DEFERASIROX (JADENU®) | tablets | 90mg, 180mg & 360mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DEGARELIX | Injection | 80mg & 120mg | R | Restricted for PBS listed indications. Blanket approval for outpatient supply with PBS prescription. |
DENOSUMAB | Injection | 60mg & 120mg | R | Restricted to Haematology and Oncology for PBS listed indications. Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
DESFERASIOXAMINE | Injection | 2g | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DESFLURANE | Solution | 240mL | Y | |
DESLORATADINE | Liquid | 2.5mg/5mL | Y | |
DESMOPRESSIN | Injection | 4mcg | Y | |
DESMOPRESSIN | Nasal Solution | 100mcg/mL | Y | |
DESMOPRESSIN | Tablet | 200mcg | Y | |
DESMOPRESSIN | Nasal Spray | 10mcg/dose | Y | |
DEXAMETHASONE | eye drop | 0.10% | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
DEXAMETHASONE | Tablet | 500mcg & 4mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
DEXAMETHASONE | Liquid | 1mg/mL | Y | |
DEXAMETHASONE | Injection | 4mg & 8mg | Y | |
DEXAMETHASONE, FRAMYCETIN & GRAMICIDIN (Sofradex®/Otodex®) | Ear Drops | 0.05%/ 0.5%/ 0.005% | Y | |
DEXAMFETAMINE | Tablet | 5mg | R | Use in attention deficit hyperactivity disorder |
DEXCHLORPHENIRAMINE | Tablet | 2mg | Y | |
DEXMEDETOMIDINE | Injection | 200mcg/2mL | R | Restricted to ICU, Palliative Care and Anaesthetics only |
DIAZEPAM | Suspension | 10mg/10mL | Y | |
DIAZEPAM | Rectal Solution | 5mg/5mL | Y | |
DIAZEPAM | Tablet | 2mg & 5mg | Y | |
DIAZEPAM | Injection | 10mg | Y | |
DIAZOXIDE | Tablet | 25mg | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
DICLOFENAC | Enteric Coated Tablet | 25mg & 50mg | Y | |
DICLOFENAC | Gel | 1% | Y | |
DICLOFENAC | Suppositories | 100mg | Y | |
DICLOXACILLIN | Capsule | 250mg & 500mg | Y | |
DIGOXIN | Suspension | 250mcg/5mL | Y | |
DIGOXIN | Tablet | 62.5mcg & 250mcg | Y | |
DIGOXIN | Injection | 50mcg & 500mcg | Y | |
DIGOXIN-SPECIFIC ANTIBODY (DigiFab®) | Injection | 40mg | R | This medication is restricted to ED, ICU and CCU for the treatment of digoxin toxicity, or for other cardiac glycoside poisoning such as Oleander and Bufotoxin (cane toad). |
DILTIAZEM | Modified release Capsules | 180mg, 240mg & 360mg | Y | |
DILTIAZEM | Tablet | 60mg | Y | |
DIMERCAPROL | Injection | 200mg | R | Stock held by RDH Emergency Department for treatment of severe lead poisoning. |
DIMETHICONE (Hedrin 15®) | Gel Spray | 4% | Y | |
DIMETHICREAM | Cream | 100g | Y | |
DINOPROSTONE | Vaginal Gel | 1mg & 2mg | R | Restricted to Specialist Obstetricians and their Registrars for induction of labour according to local guidelines. |
DINOPROSTONE CR | Controlled Release Pessary | 10mg | R | Restricted to Specialist Obstetricians and their Registrars for induction of labour according to local guidelines. |
DIPHENOXYLATE & ATROPINE (Lomotil®) | Tablet | 2.5/0.025mg | Y | |
DIPHTHERIA & TETANUS VACCINE (ADT®) | Injection | Y | ||
DIPHTHERIA TETANUS & PERTUSSIS VACCINE (Boostrix®) | Injection | Y | ||
DIPHTHERIA, TETANUS, PERTUSSIS & POLIO (Infanrix-IPV®) | Injection | Y | ||
DISODIUM EDETATE | Injection | 3% | Y | |
DOBUTAMINE | Injection | 250mg | Y | |
DOCETAXEL | Injection | 20mg, 80mg & 160mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
DOCUSATE & SENNA (Coloxyl & Senna®) | Tablet | 50/8mg | Y | |
DOCUSATE SODIUM | Tablet | 50mg & 120mg | Y | |
DOCUSATE SODIUM EAR DROPS (Waxsol®) | Ear Drops | Y | ||
DOLUTEGRAVIR | Tablet | 50mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DOLUTEGRAVIR, ABACAVIR & LAMIVUDINE | Tablet | 50mg+600mg+ 300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DOLUTEGRAVIR & LAMIVUDINE | Tablet | 50mg+300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DOLUTEGRAVIR & RILPIVIRINE | Tablet | 50mg+25mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
DOMPERIDONE | Tablet | 10mg | Y | Blanket outpatient approval for the stimulation of lactation. |
DONEPEZIL | Tablet | 5mg & 10mg | Y | |
DOPAMINE | Injection | 200mg | Y | |
DORNASE ALFA | Nebulised solution | 2.5mg/2.5mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Restricted for use by with respiratory specialists/advanced trainees with experience in its use for empyema management. |
DOSULEPIN (DOTHIEPIN) | Tablet | 75mg | Y | |
DOSULEPIN (DOTHIEPIN) | Capsule | 25mg | Y | |
DOXORUBICIN | Injection | 50mg/25mL & 200mg/100mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
DOXORUBICIN LIPOSOMAL | Injection | 20mg/10mL & 50mg/25mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
DOXYCYCLINE | Tablet | 100mg | Y | Blanket outpatient approval for melioidosis eradication in patients who cannot tolerate trimethoprim/sulfamethoxazole approved by IFD. |
DOXYCYCLINE | Injection | 100mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
DOXYLAMINE | Tablets | 25mg | Y | |
DROPERIDOL | Injection | 2.5mg/1mL 10mg/2mL | Y/ R | 10mg/2mL restricted to Emergency Departments and Mental Health |
DULAGLUTIDE | Syringe | 1.5mg | R | Restricted to PBS indications (Use restricted to continuation treatment only; Treatment initiation requires IPU approval) |
DULOXETINE | Capsules | 30mg & 60mg | R | Restricted to PBS indications. |
DUTASTERIDE/TAMSULOSIN | Capsules | 500mcg/400mcg | R | Restricted to PBS indications. |
ECULIZUMAB | Injection | 300mg/30mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Note: Eculizumab is reimbursed by the PBS under S100 HSD arrangements for both outpatients and public hospital admitted patients for the treatment of aHUS. |
EDROPHONIUM | Injection | 10mg | Y | |
EFAVIRENZ | Tablet | 200mg & 600mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
EMICIZUMAB | Syringe | 30mg/mL 60mg/0.4mL 105mg/0.7mL & 150mg/1mL | R | Restricted to inpatient and outpatient Haematology patients that meet the National Product List (NPL) restrictions. |
EMPAGLIFLOZIN | Tablet | 10mg & 25mg | Y | |
EMTRICITABINE, RILPIVIRINE & TENOFOVIR ALAFENAMIDE | Tablet | 200mg+25mg+25mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
EMTRICITABINE & TENOFOVIR ALAFENAMIDE | Tablet | 200mg+25mg & 200mg+10mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ENALAPRIL | Tablet | 5mg, 10mg, 20mg | Y | For paediatric patients with heart failure or breastfeeding women with hypertension or heart failure |
ENOXAPARIN | Injection | 20mg, 40mg, 60mg, 80mg 100mg, 120mg & 150mg | Y | |
ENTECAVIR | Tablet | 500mcg & 1mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Blanket outpatient approval for the prevention of hepatitis B virus reactivation or progression in patients >16 years old who are immunosuppressed or live in a remote area and do not meet PBS criteria restricted to prescribers under the direction of Infectious Diseases or Liver Clinic Specialists. |
EPHEDRINE | Injection | 30mg | Y | |
EPIRUBICIN | Injection | 2mg/mL | R | Restricted to Oncology/Haematologist use only |
EPLERENONE | Tablet | 25mg & 50mg | R | Restricted to Cardiology |
EPOPROSTENOL | Injection | 500 mcg & 1.5mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
EPTACOG ALPHA (NovoSeven RT®) | Injection | 1mg & 2mg | R | Available at RDH only. Restricted to ICU, stock is kept in ICU. 1.2mg strength is non-formulary and stock is supplied by blood transfusion services for Haematology protocol use. |
ERGOMETRINE | Injection | 500mcg | Y | |
ERGOMETRINE & OXYTOCIN | Injection | 500mcg/5 IU | Y | |
ERLOTINIB | Tablet | 25mg, 100mg & 150mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
ERTAPENEM | Injection | 1g | Y | |
ERYTHROMYCIN | Capsule | 250mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
ERYTHROMYCIN ETHYL SUCCINATE | Suspension | 200mg/5mL | Y | |
ERYTHROMYCIN LACTOBIONATE | Injection | 1g | Y | |
ESCITALOPRAM | Tablets | 10mg & 20mg | R | PBS indications only. |
ESMOLOL | Injection | 100mg/10mL | Y | |
ESTRIOL (ESTRADIOL VALERATE) | Tablet | 1mg | Y | |
ESTRIOL (ESTRADIOL) | Patch | 25mcg, 50mcg & 100mcg | Y | |
ESTRIOL (ESTRADIOL) | Implant | 100mg | Y | |
ESTRIOL (ESTRIOL) | Vaginal Cream | 1mg/g | Y | |
ETANERCEPT | Injection | 25mg | Y | |
ETHAMBUTOL | Tablet | 100mg & 400mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of Tuberculosis approved by TB clinic/IFD. |
ETONOGESTREL (Implanon NXT®) | Implant | 68mg | R | Restricted to: O&G use for inpatients where access to Implanon NXT® insertion in primary care is not appropriate or not available or Paediatricians (for TEHS only) for high risk adolescents |
ETOPOSIDE | Capsule | 50mg & 100mg | R | Restricted to Haematology and Oncology for PBS listed indications. Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
ETOPOSIDE | Injection | 100mg & 1gram | R | Restricted to Haematology and Oncology for PBS listed indications. |
ETRAVIRINE | Tablet | 200mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
EVEROLIMUS | Tablet | 500mcg & 750mcg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
EXEMESTANE | Tablet | 25mg | Y | |
EZETIMIBE | Tablet | 10mg | R | Restricted for use in patients who are on an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled |
FAMOTIDINE | Tablet | 20mg & 40mg | Y | |
FENOFIBRATE | Tablet | 48mg & 145mg | Y | |
FENTANYL | Injection | 100mcg & 500mcg | Y | |
FENTANYL | Patch | 12mcg, 25mcg, 50mcg, 75mcg & 100mcg | Y | |
FENTANYL (ABSTRAL®) | Sublingual Tablets | 100mcg, 300mcg & 400mcg | R | Restricted to Palliative Care as per the PBS Criteria |
FERRIC CARBOXYMALTOSE (IRON) | Injection | 500mg/10mL & 100mg/2mL | R | Restricted to use in remote health according to approved protocol. All stock to be dispensed from pharmacy on an individual patient basis. Restricted to use in outpatients who are able to access supply via a PBS prescription (500mg/10mL strength only). Restricted to use in inpatients for the following indications; Previously documented adverse drug reaction to iron polymaltose. Heart failure with a documented fluid restriction. |
FERRIC DERISOMALTOSE (IRON) | Injection | 500mg/5mL | R | Restricted to use in outpatients who are able to access supply via a PBS prescription. Restricted to use in inpatients for the following indications for patients requiring more than 1000mg of elemental iron: Previously documented adverse drug reaction to iron polymaltose. Heart failure with a documented fluid restriction. |
FERRIC SUBSULPHATE (IRON) | Gel | 21% | R | Restricted to gynaecology use only. |
FERROUS FUMARATE & FOLIC ACID (Ferro-F®) | Modified Release Tablets | 310mg/350mcg | Y | |
FERROUS SULFATE HEPTAHYDRATE | Liquid | 150mg/5mL | Y | |
FERROUS SULFATE HEPTAHYDRATE & VITAMIN C | Modified Release Tablets | 325mg/500mg | Y | |
FERROUS SULFATE HEPTAHYDRATE (Ferrograd®) | Tablet | 325mg | Y | |
FILGRASTIM | Injection | 300mcg & 480mcg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
FLECAINIDE | Injection | 150mg | Y | |
FLECAINIDE | Tablet | 50mg & 100mg | Y | |
FLUCLOXACILLIN | Injection | 500mg & 1g | Y | |
FLUCLOXACILLIN | Infusor | 4g, 6g, 8g & 12g | Y | |
FLUCLOXACILLIN | Suspension | 250mg/5mL | Y | |
FLUCONAZOLE | Capsule | 50mg, 100mg & 200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Restricted to Haematology and Oncology for PBS listed indications. Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases and for antifungal prophylaxis in haematological malignancies with immunosuppressive chemotherapy. |
FLUCONAZOLE | Injection | 100mg & 200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Restricted to Haematology and Oncology for PBS listed indications. |
FLUCONAZOLE | Suspension | 50mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Restricted to Haematology and Oncology for PBS listed indications. |
FLUCYTOSINE | Capsule | 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
FLUDARABINE | Injection | 50mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
FLUDARABINE | Tablet | 10mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
FLUDROCORTISONE | Tablet | 100mcg | Y | |
FLUMAZENIL | Injection | 500mcg | Y | |
FLUORESCEIN | Strips | 1mg | Y | |
FLUORESCEIN SODIUM | Minims | 2% | Y | |
FLUORESCEIN SODIUM | Injection | 10% | Y | |
FLUOROMETHOLONE (Flucon®) | Eye drops | 0.10% | R | Restricted to Ophthalmologist use only |
FLUOROMETHOLONE ACETATE (Flarex®) | Eye drops | 0.10% | R | Restricted to Ophthalmologist use only |
FLUOROURACIL | Infusion | R | Restricted to Haematology and Oncology for PBS listed indications. | |
FLUOROURACIL | Injection | 500mg, 1gram, 2.5gram & 5gram | R | Restricted to Haematology and Oncology for PBS listed indications. |
FLUOXETINE | Capsule & Dispersible tablets | 20mg | R | Dispersible tablets are restricted to Paediatrics and Mental Health |
FLUPENTHIXOL DECANOATE | Injection | 20mg, 40mg & 100mg | Y | *Order on request |
FLUTICASONE | Inhaler | 125mcg, 250mcg & 50mcg | Y | |
FLUTICASONE & SALMETEROL (Seretide®) | Accuhaler | 100/50mcg, 250/50mcg & 500/50mcg | Y | |
FLUTICASONE & SALMETEROL (Seretide®) | Inhaler | 50/25mcg, 125/25mcg & 250/25mcg | Y | |
FLUTICASONE / VILANTEROL (Ellipta Breo®) | Inhaler | 100mcg/25mcg, 200mcg/25mcg | Y | |
FOLIC ACID | Injection | 15mg | Y | |
FOLIC ACID | Tablet | 500mcg & 5mg | Y | Blanket outpatient approval for prevention of sulfamethoxazole/trimethoprim induced folate deficiency in patients receiving treatment for melioidosis. |
FONDAPARINUX | Injection | 2.5mg/0.5mL | R | Restricted to use by ICU and Haematology for Heparin Inducted Thrombocytopenia/Thrombosis (HIT). |
FORMALIN | Solution | 10% | Y | |
FOSAMPRENAVIR | Tablet | 700mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
FOSAPREPITANT | Injection | 150mg | R | Restricted to Haematology and Oncology for PBS listed indications in patients who cannot tolerate orals |
FOSFOMYCIN | Granules for Solution | 3g Sachet | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for multi-resistant UTI approved by IFD |
FOSFOMYCIN | Injection | 4g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
FOTEMUSTINE | Injection | 208mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
FUROSEMIDE | Solution (SyrSpend®) | 50mg/5mL | Y | PBS 20mg tablets should be prescribed where doses can be divided into 5mg increments. Blanket outpatient approval for paediatrics where the dose is not in 5mg increments. |
FUROSEMIDE | Injection | 20mg & 250mg | Y | |
FUROSEMIDE | Tablet | 20mg, 40mg & 500mg | Y | |
GABAPENTIN | Capsule | 100mg, 300mg, 400mg & 800mg | Y | Blanket outpatient approval for the treatment of neuropathic pain. |
GANCICLOVIR | Injection | 500mg | S | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
GEFITINIB | Tablet | 250mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
GEMCITABINE | Injection | 200mg, 1g & 2g | R | Restricted to Haematology and Oncology for PBS listed indications. |
GENTAMICIN | Injection | 80mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
GENTAMICIN/CITRATE | Syringe | 10mg/31.3mg | Y | |
GLECAPREVIR/PIBRENTASVIR (Maviret®) | Tablets | 100/40mg | S | Restricted to specialists working in the liver clinic running the HCV treatment program. For initiation in outpatients via the Highly specialised Drugs Program (Section 100). Refer to PBS Criteria. |
GLICLAZIDE | Modified release tablets | 30mg | Y | |
GLICLAZIDE | Modified release tablets | 60mg | R | For discharge prescriptions only |
GLICLAZIDE | Tablet | 80mg | Y | |
GLIMEPIRIDE | Tablet | 1mg, 2mg & 4mg | Y | |
GLUCAGON | Injection | 1mg | Y | |
GLUCOSE | Injection | 10% | Y | |
GLUCOSE | Injection | 5% - 500mL & 1L | Y | |
GLUCOSE | Injection & mini-jet | 50% - 50mL, 500mL | Y | Mini-jet is restricted to resuscitation room in the emergency department |
GLUCOSE & SODIUM CHLORIDE | 2.5%/0.45%, 4%/0.18% | 500mL & 1L | Y | |
GLUCOSE & SODIUM CHLORIDE | 5%/0.9% | 1L | Y | |
GLUCOSE TOLERANCE TEST | Solution | 75g | Y | |
GLYCEROL | Suppositories | 700mg, 2.8g | Y | |
GLYCEROL BP | Solution | 200mL | Y | |
GLYCERYL TRINITRATE | Sublingual Tablet | 300mcg, 600mcg | Y | *300mcg added for short-term listing while 600mcg is out of stock. |
GLYCERYL TRINITRATE | Ointment | 0.20% | Y | |
GLYCERYL TRINITRATE | Spray | 400mcg | Y | |
GLYCERYL TRINITRATE | Patch | 5mg/24 hour & 10mg/24 hour | Y | |
GLYCERYL TRINITRATE | Injection | 50mg | Y | |
GLYCINE | Irrigation | 1.50% | Y | |
GLYCOPYRRONIUM BROMIDE | Injection | 200mcg | Y | Blanket outpatient approval for Palliative care patients. |
GOSERELIN | Implant | 3.6mg & 10.8mg | R | Restricted to PBS listed indications AND for Ovarian Suppression with chemotherapy (3.6mg only). Blanket approval for outpatient supply with PBS prescription. |
GRAMICIDIN/NEOMYCIN/NYSTATIN/TRIAMCINOLONE ACETONIDE (Otocomb Otic®) | Ear Ointment | 0.25mg/2.5mg/100,000 units/1mg/g | Y | |
GRANISETRON | Tablet | 2mg | R | Restricted to Haematology and Oncology for PBS listed indications (outpatient/same day admission only). |
GRISEOFULVIN | Tablet | 125mg & 500mg | Y | |
HAEMOFILTRATION (CITRATE) | Solution | R | Restricted to ICU only | |
HAEMOFILTRATION LACTATE FREE | Solution | R | Restricted to ICU only | |
HAEMOPHILUS INFLUENZA B VACCINE | Injection | Y | ||
HALOPERIDOL | Tablet | 500mcg, 1.5mg & 5mg | Y | |
HALOPERIDOL | Injection | 5mg | Y | Blanket outpatient approval for Palliative care patients. |
HALOPERIDOL | Solution | 10mg/5mL | Y | |
HALOPERIDOL DECANOATE | Injection | 50mg | Y | |
HEPARIN SODIUM | Injection | 5000units/0.2mL, 5000units/5mL, 25000units/5mL | Y | |
HEPARINISED SALINE | Injection | 50units/5mL | Y | |
HEPARINOIDS (HEPARINOID CREAM) | Cream | 0.3% | Y | |
HEPATITIS A VACCINE | Injection | Y | ||
HEPATITIS A&B VACCINE | Injection | Y | ||
HEPATITIS B VACCINE (ADULT) | Injection | Y | Available brands: H-B-Vax II (Adult)® or Engerix B (Adult)® | |
HEPATITIS B VACCINE (PAEDIATRIC) | Injection | Y | Available brands: H-B-Vax II (Paediatric)® or Engerix B (Paediatric)® | |
HEPATITIS B VACCINE (DIALYSIS FORMULATION) | Injection | Y | Available brands: H-B-Vax II (Dialysis formulation)® | |
HEPATITIS B, Hib & POLIO (Infanrix-Hexa®) | Injection | Y | ||
HEPATITIS-B VACCINE (DIALYSIS) | Injection | 40mcg/mL | Y | |
HUMAN PAPILLOMAVIRUS (HPV) VACCINE | Injection | Y | ||
HYALURONIDASE | Injection | 1500 u | Y | |
HYDRALAZINE | Injection | 20mg | Y | |
HYDRALAZINE | Tablet | 25mg & 50mg | Y | |
HYDROCHLORIC ACID | Injection | 2M | Y | |
HYDROCHLOROTHIAZIDE | Tablet | 25mg | Y | |
HYDROCORTISONE | Ointment | 1% | Y | |
HYDROCORTISONE | Cream | 1% | Y | |
HYDROCORTISONE | Tablet | 4mg & 20mg | Y | |
HYDROCORTISONE | Eye ointment | 1% | Y | |
HYDROCORTISONE | Foam | 10% | Y | |
HYDROCORTISONE SODIUM SUCCINATE | Injection | 100mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
HYDROCORTISONE/ CLOTRIMAZOLE | Cream | 1% | Y | |
HYDROGEN PEROXIDE | Solution | 3% | Y | |
HYDROMORPHONE | Tablet | 2mg, 4mg & 8mg | R | Restricted to Palliative Care, Rehabilitation and Pain teams only |
HYDROMORPHONE | Liquid | 5mg/5mL | R | Restricted to Palliative Care, Rehabilitation and Pain teams only |
HYDROMORPHONE | Injection | 2mg, 10mg & 50mg | R | Restricted to Palliative Care, Rehabilitation and Pain teams only. Blanket outpatient approval for chronic pain in palliative care patients. |
HYDROXOCOBALAMIN | Injection | 1000mcg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
HYDROXYCHLOROQUINE | Tablet | 200mg | Y | |
HYDROXYCARBAMIDE (HYDROXYUREA) | Capsule | 500mg | Y | |
HYOSCINE BUTYLBROMIDE | Injection | 20mg | Y | Blanket outpatient approval for Palliative care patients. |
HYOSCINE BUTYLBROMIDE | Tablet | 10mg | Y | |
HYOSCINE HYDROBROMIDE | Injection | 400mcg | Y | Blanket outpatient approval for excess respiratory tract secretions. |
HYOSCINE HYDROBROMIDE | Tablet | 300mcg | R | For the treatment of hypersalivation restricted to inpatients who have clozapine induced sialorrhoea (CIS). |
HYPERTONIC SALINE | Inhalation | 6% | R | Restricted to cystic fibrosis (CF) or non-CF bronchiectasis in paediatric patients. Blanket approval for outpatient supply to CF or non-CF bronchiectasis in paediatric patients. |
HYPROMELLOSE | Eye drop | 0.50% | Y | |
HYPROMELLOSE/ CARBOMER GEL (Genteal®) | Eye drop | 3mg/2mg | Y | |
IBUPROFEN | Injection | 10mg | Y | |
IBUPROFEN | Tablet | 200mg & 400mg | Y | |
IBUPROFEN | Syrup | 100mg/5mL | Y | |
ICATIBANT ACETATE | Pre-filled Syringe | 30mg/3mL | R | Restricted to Emergency Medicine consultants under the advice of the duty immunologist for the emergency treatment of: Alteplase induced angioedema; Severe angioedema affecting the airway due to ACE inhibitors; Symptomatic treatment of acute attacks of hereditary angioedema in adults with C1 esterase inhibitor deficiency. |
IDARUBICIN | Injection | 5mg & 10mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
IDARUBICIN | Capsules | 5mg & 10mg | R | Restricted to Haematology and Oncology for PBS listed indications AND for Myeloma. |
IFOSFAMIDE | Injection | 1gram & 2gram | R | Restricted to Haematology and Oncology for PBS listed indications. |
ILOPROST | Injection | 20mcg/2mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
INCREMIN IRON MIXTURE | Mixture | Y | ||
INDAPAMIDE | Modified Release Tablets | 1.5mg | Y | |
INDOMETHACIN | Capsule | 25mg | Y | |
INDOMETHACIN | Injection | 1mg | Y | |
INDOMETHACIN | Suppositories | 100mg | Y | |
INFLIXIMAB | Injection | 100mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
INFLUENZA VACCINE | Injection | 60 microg/0.5mL | Y | |
INSULIN ASPART Injection (NovoRapid®) | Flexpen (3mL), Penfill (3mL) & Vial (10mL) | 100 units/mL | Y | |
INSULIN ASPART PROTAMINE 70 units/mL + INSULIN ASPART 30 units/mL Injection (Novomix 30 ®) | Flexpen (3mL) & Penfill (3mL) | 100 units/mL | Y | |
INSULIN ASPART 30 units/mL + INSULIN DEGLUDEC 70 units/mL injection (Ryzodeg® 70/30) | Flexpen (3mL) & Penfill (3mL) | 100 units/mL | Y | |
INSULIN GLARGINE Injection (Lantus®/Optisulin®) | Penfill & Vial | 100 units/mL | Y | |
INSULIN ISOPHANE Injection (Protaphane®) | Vial, Innolet, Novolet and Penfill | 100 units/mL | Y | |
INSULIN ISOPHANE NPH Injection (Humulin NPH®) | Penfill | 100 units/mL | R | To be used second line when other formulary insulin products are not suitable, or as continuing therapy for patients commenced in the community. |
INSULIN LISPRO Injection (Humalog®) | Penfill, Kwik Pen | 100 units/mL | R | To be used second line when other formulary insulin products are not suitable, or as continuing therapy for patients commenced in the community. |
INSULIN LISPRO 25 units/mL /INSULIN LISPRO PROTAMINE 75 units/mL Injection (Humalog 25®) | Flexpen (3mL) & Penfill (3mL) | 100 units/mL | R | To be used second line when other formulary insulin products are not suitable, or as continuing therapy for patients commenced in the community. |
INSULIN NEUTRAL (Actrapid®) | Penfill & Vial | 100 units/mL | Y | |
INSULIN NEUTRAL/ ISOPHANE (Mixtard 30/70®) | Vial, Innolet & Penfill | 100 units/mL | Y | |
IODINE/POTASSIUM IODIDE (Lugol’s®) | Solution (100mL) | 5%/10% w/v | Y | |
IPILIMUMAB | Injection | 213mg | R | For oncologist use only - restricted to patients eligible for compassionate supply programme. |
IPILIMUMAB | Injection | 50mg & 200mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
IPRATROPIUM | Inhaler | 21microg | Y | |
IPRATROPIUM | nebulised solution | 500microg | Y | |
IRBESARTAN | Tablet | 75mg, 150mg & 300mg | Y | |
IRBESARTAN &HYDROCHLOROTHIAZIDE | Tablet | 150/12.5mg & 300/12.5mg | Y | |
IRINOTECAN | Injection | 40mg, 100mg & 500mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
IRON POLYMALTOSE | Injection | 100mg | Y | |
ISOFLURANE | Liquid for inhalation | Y | ||
ISONIAZID | Tablet | 100mg & 300mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of active or latent tuberculosis by TB clinic/IFD. |
ISONIAZID & RIFAMPICIN | Tablet | 50mg + 75mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of active or latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ISONIAZID & RIFAMPICIN | Tablet | 75mg + 150mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of active or latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ISONIAZID & RIFAPENTINE | Tablet | 300mg + 300mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ISONIAZID, PYRAZINAMIDE & RIFAMPICIN | Tablet | 50mg +150mg + 75mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of active or latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ISONIAZID, ETHAMBUTOL, PYRAZINAMIDE & RIFAMPICIN | Tablet | 75mg + 275mg + 400mg + 150mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of active or latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
ISOPRENALINE | Injection | 200mcg | Y | |
ISOPROPYL ALCOHOL BP | Solution | Y | ||
ISOSORBIDE DINITRATE | Sublingual Tablet | 5mg | Y | |
ISOSORBIDE MONONITRATE | Modified Release Tablets | 60mg | Y | |
ITRACONAZOLE | Solution | 50mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
ITRACONAZOLE (LOZANOC®) | Capsule | 50mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
IVABRADINE | Tablet | 5mg & 7.5mg | R | Restricted to Cardiologists for treatment of Chronic heart failure for patients that meet the PBS criteria. Restricted to Cardiology for use in patients with a heart rate greater than 60 beats per minute prior to computed tomography coronary angiography (CTCA) when beta blockers and/or calcium channel blockers are contraindicated or insufficient. |
IVERMECTIN | Tablet | 3mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
KETAMINE | Injection | 200mg | Y | |
KETAMINE | Wafer | 25mg | R | Restricted to use by RDH Acute Pain Service (APS) as an analgesic agent for painful procedures on the ward. |
KETOCONAZOLE | Shampoo | 2% | Y | |
KETOROLAC | Injection | 30mg | Y | |
KETOROLAC | Eye drop | 0.50% | Y | |
KIDNEY PERFUSION | Infusion | R | Restricted for kidney harvesting | |
LABETALOL | Tablet | 100mg | Y | |
LABETALOL | Injection | 50mg/10mL | R | Restricted to ICU/OT for severe pre-eclampsia - refer to protocol on the PGC. Restricted to ED/ICU for the management of hypertension in Stroke Thrombolysis or Pulmonary Embolism thrombolysis – refer to protocols on the PGC. |
LACTASE | Drops | Y | ||
LACTULOSE | Syrup | Y | ||
LAMIVUDINE | Solution | 10mg/mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
LAMIVUDINE | Tablet | 100mg, 150mg & 300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
LAMIVUDINE & ZIDOVUDINE | Tablet | 150mg+300mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
LAMOTRIGINE | Tablet | 5mg, 25mg, 50mg & 100mg | Y | |
LANOLIN BP | Ointment | 5gram | Y | |
LANREOTIDE | Injection | 60mg & 90mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
LATANOPROST | Eye drop | 50mcg | Y | |
LENALIDOMIDE | Capsule | 5mg, 10mg, 15mg & 25mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
LETROZOLE | Tablet | 2.5mg | R | Restricted to Haematology and Oncology |
LEUCOVORIN | Tablet | 15mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
LEUCOVORIN | Injection | 50mg, 100mg, 300mg & 1gram | R | Restricted to Haematology and Oncology for PBS listed indications. |
LEVAMISOLE | Tablets | 50mg | R | Blanket outpatient/inpatient approval. Restricted to Paediatric nephrologists. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
LEVETIRACETAM | Injection | 500mg/5mL | Y | |
LEVETIRACETAM | Solution | 500mg/5mL | Y | |
LEVETIRACETAM | Tablet | 250mg, 500mg & 1000mg | Y | |
LEVODOPA/ CARBIDOPA MONOHYDRATE (Kinson® or Sinemet®) | Tablet | 100/25mg & 250/25mg | Y | |
LEVODOPA/BENSERAZIDE (Madopar®) | Tablet | 100/25mg | Y | |
LEVODOPA/BENSERAZIDE (Madopar®) | Capsule | 100mg/25mg & 200mg/50mg | Y | |
LEVODOPA/BENSERAZIDE(Madopar® HBS) | Controlled Release Capsules | 100/25mg | Y | |
LEVODOPA/CARBIDOPA MONOHYDRATE (Sinemet CR®) | Controlled Release Tablets | 200/50mg | Y | |
LEVOFLOXACIN | Tablets | 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. Blanket outpatient/inpatient approval for the treatment of Helicobacter pylori (H. pylori) infection following documented treatment failure with a clarithromycin based regimen; or, for primary treatment of H. pylori infection in a patient who cannot tolerate clarithromycin (due to drug allergy or unavoidable drug interactions). |
LEVOMEPROMAZINE | Injection | 25mg/mL | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. Blanket outpatient/inpatient approval for intractable nausea and vomiting and second line sedative for delirium/agitation in palliative care patients. |
LEVONORGESTREL | Tablet | 1.5mg | Y | |
LEVONORGESTREL (Mirena®) | Intra-uterine system (IUS) | 52mg | R | Restricted to O&G use for: Inpatients where access to Mirena® insertion in primary care is not appropriate or not available. Outpatients where supply cannot be accessed via the PBS. All Mirena® will be supplied by hospital pharmacies on an individual patient basis. |
LEVOSIMENDAN | Injection | 12.5mg | R | Restricted to ICU. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
LEVOTHYROXINE SODIUM (Brands: Eutroxsig and Oroxine only) | Tablet | 50mcg & 100mcg | Y | |
LEVOTHYROXINE | Injection | 200mcg/mL | R | Restricted to Endocrinologists, Emergency Medicine and Intensive Care Specialists for the treatment of myxoedema coma and symptomatic hypothyroidism in patients unable to be treated effectively with oral medications This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
LIDOCAINE/ ADRENALINE | Injection | 1%/1:100,000, 2%/1:80,000, 2%/1:200,000 | Y | |
LIDOCAINE | Ointment | 5% | Y | |
LIDOCAINE | Injection | 0.5%, 1% & 2% & 500mg | Y | |
LIDOCAINE | Topical Solution | 4% | Y | |
LIDOCAINE | Jelly | 2% | Y | |
LIDOCAINE | Catheter Syringe | 2% | Y | |
LIDOCAINE | Spray | 10% | Y | |
LIDOCAINE | Oral Gel | 2% | Y | |
LIDOCAINE / GLUCOSE | Injection | 0.4%/5% | Y | |
LIDOCAINE/PRILOCAINE (Emla®) | Patch | 2.5%/2.5% | Y | |
LIGNOCAINE/PHENYEPHRINE (Co-phenylcaine Forte®) | Nasal Spray | 5%/0.5% | Y | |
LINAGLIPTIN | Tablet | 5mg | Y | |
LINEZOLID | Infusion | 600mg/300mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
LINEZOLID | Tablet | 600mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for treatment of infections approved by IFD. |
LINEZOLID | Suspension | 100mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
LIOTHYRONINE | Injection | 20mcg | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
LIOTHYRONINE | Tablet | 20mcg | Y | |
LIPASE/AMYLASE/PROTEASE (Creon®) | Micro granules | 5000 units | Y | |
LIPASE/AMYLASE/PROTEASE (Creon®) | Capsule | 10,000 & 25,000 units | Y | |
LIPID EMULSION (SMOFlipid®) | Emulsion | 20% | Y | Blanket approval for Renal outpatients |
LIQUID PARAFFIN EMULSION (Parachoc®) | Emulsion | Y | ||
LIQUID PARAFFIN LIGHT (Hamilton®) | Bath Oil | 500mL | Y | |
LIRAGLUTIDE (Saxenda®) | Syringe | 6mg/mL | R | Blanket outpatient approval for RDPH Weight Management Clinic |
LITHIUM CARBONATE | Tablet | 250mg | Y | |
LITHIUM CARBONATE | Modified Release Tablets | 450mg | Y | |
LOPERAMIDE (Gastro-Stop®) | Capsule | 2mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
LOPINAVIR & RITONAVIR | Tablet | 200mg+50mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Or Restricted to the ASCOT or REMAP CAP Trial as prescribed by the infectious disease and ICU consultants. |
LOPINAVIR & RITONAVIR | Liquid | 400mg+100mg/5mL (60mL) | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Or Restricted to the ASCOT or REMAP CAP Trial as prescribed by the infectious disease and ICU consultants. |
LORATADINE | Tablet | 10mg | Y | |
LORAZEPAM | Tablet | 1mg & 2.5mg | Y | |
LUBRICATING JELLY | Sachets or Tube | Y | ||
MACITENTAN | Tablets | 10mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
MACROGOL/POTASSIUM CHLORIDE/SODIUM BICARBONATE/SODIUM CHLORIDE LAXATIVE (Lax®) | Sachets | 13.125g/46.6mg/178.5mg/350.7mg | Y | |
MAGNESIUM ASPARTATE TETRAHYDRATE | Tablet | 500mg | Y | |
MAGNESIUM CHLORIDE | Injection | 5mmol | Y | |
MAGNESIUM SULPHATE | Injection | 2mmol & 10mmol | Y | |
MAGNESIUM SULPHATE CO (Magnoplasm®) | Paste | Y | ||
MANNITOL | Injection | 20% | Y | |
MEDIUM CHAIN TRIGLYCERIDE | Oil | Y | ||
MEDIUM CHAIN TRIGLYCERIDES | Emulsion | Y | ||
MEDROXYPROGESTERONE | Tablet | 10mg & 100mg | Y | |
MEDROXYPROGESTERONE | Injection | 150mg | Y | |
MEFLOQUINE | Tablet | 250mg | Y | |
MELATONIN | Modified Release Tablet | 2mg | Y | Restricted to Geriatrics, Rehabilitation and General medicine for inpatient use only for patients greater than 55 years of age with sleep disturbance, where other hypnotics are contraindicated (e.g. falls risk, dementia, behavioural disturbance), and non-pharmacological measures have been ineffective. For a maximum of 13 weeks. |
MELPHALAN | Tablet | 2mg | Y | Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
MEMANTINE | Tablet | 10mg | R | Restricted to patients who meet the PBS criteria |
MENINGOCOCCAL ACWY VACCINE 4vMenCV | Injection | 0.5mL | Y | For patients eligible under National Immunisation Program (NIP) Schedule only. |
MENINGOCOCCAL C VACCINE (NeisVac-C®) | Injection | Y | ||
MENINGOCOCCAL MULTICOMPONENT GROUP B VACCINE (Bexsero®) | Injection | 0.5mL | Y | For patients eligible under National Immunisation Program (NIP) Schedule only. |
MERCAPTOPURINE | Tablet | 50mg | Y | |
MEROPENEM | Injection | 500mg & 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
MESALAZINE | Enteric Coated Tablet | 250mg | Y | |
MESNA | Injection | 400mg & 1g | R | Restricted to Haematology and Oncology for PBS listed indications. |
MESNA | Tablets | 400mg & 600mg | R | Restricted to Haematology and Oncology for the prevention of haemorrhagic cystitis with cyclophosphamide or ifosfamide. |
METARAMINOL | Injection | 10mg/mL | Y | |
METARAMINOL | Pre-filled syringe | 2.5mg/5mL & 5mg/10mL | Y | Stocked syringes: RDH, GDH, KH: 2.5mg/5mL ASH: 5mg/10mL |
METFORMIN | Tablet | 500mg, 850mg & 1000mg | Y | |
METFORMIN MR | Modified Release Tablet | 500mg & 1000mg | Y | |
METHADONE | Tablet | 10mg | Y | |
METHADONE | Injection | 10mg | Y | |
METHADONE | Syrup | 5mg/mL | R | Restricted to Addiction medicine prescribers, Pain team and Palliative Care. |
METHOTREXATE | Tablet | 2.5mg & 10mg | Y | Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
METHOTREXATE | Syringe | 10mg, 12mg, 15mg, 20mg, 25mg, 50mg & 75mg | Y | |
METHOTREXATE | Injection | 5mg, 50mg, 500mg, 1gram & 5gram | R | Restricted to Haematology and Oncology for PBS listed indications. |
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA | Injection | 30mcg, 50mcg, 75mcg, 100mcg, 120mcg, 200mcg & 360mcg. | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
METHOXYFLURANE | Liquid for inhalation | 3mL | R | Restricted to haematology use for analgesia during bone marrow biopsy procedure |
METHYL SALICYLATE/EUCALYPTUS MENTHOL | Rub | Y | ||
METHYLDOPA SESQUIHYDRATE | Tablet | 250mg | Y | |
METHYLENE BLUE | Injection | 1% (50mg) | Y | |
METHYLNALTREXONE | Injection | 12mg | R | Palliative Care and ICU only for treatment of opioid-induced constipation in patients who have failed to respond to laxatives. |
METHYLPHENIDATE | Tablet | 10mg | R | Use in attention deficit hyperactivity disorder |
METHYLPREDISOLONE ACETATE (Depo- Nisolone®) | Depot injection | 40mg/mL | Y | |
METHYLPREDISOLONE ACETATE in FATTY OINTMENT | Ointment | 0.1% | Y | |
METHYLPREDNISOLONE SODIUM SUCCINATE | Injection | 1g & 40mg | Y | |
METOCLOPRAMIDE | Injection | 10mg | Y | |
METOCLOPRAMIDE | Tablet | 10mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
METOPROLOL | Modified Release Tablet | 23.75mg, 47.5mg, 95mg & 190mg | Y | |
METOPROLOL | Tablet | 50mg & 100mg | Y | |
METOPROLOL TARTRATE | Injection | 1mg | Y | |
METRONIDAZOLE | Suspension | 200mg/5mL | Y | |
METRONIDAZOLE | Suppositories | 500mg | Y | |
METRONIDAZOLE | Tablet | 200mg & 400mg | Y | |
METRONIDAZOLE | Infusion | 500mg | Y | |
MICONAZOLE | Oral gel | 2% | Y | |
MIDAZOLAM | Injection | 5mg/mL, 5mg/5mL, 15mg/3mL & 50mg/10mL | Y | Blanket outpatient approval for epilepsy in paediatric patients (5mg/mL plastic ampoules). Blanket outpatient approval for palliative care patients for various indications. |
MIDODRINE | Tablet | 2.5mg & 5mg | R | Blanket outpatient approval for management of symptomatic hypotension (including orthostatic and intradialytic) where non-pharmacological management has failed, restricted to medical and renal physicians. |
MIFEPRISTONE | Tablet | 200mg | Y | Restricted to Obstetrics & Gynaecology specialists for the medical termination of pregnancy beyond the first trimester up to 22 completed weeks gestation and beyond 22 weeks for foetal death in utero only. |
MIFEPRISTONE/ MISOPROSTOL (MS 2 STEP®) | Tablet | 200mg/200mcg | Y | Restricted to Katherine Hospital only, for medical termination of an intrauterine pregnancy (MTOP) up to 63 days gestation (PBS indications). MS2Step can be accessed in community pharmacies in other areas of the NT. |
MILRINONE | Injection | 10mg/10mL | R | Restricted to ICU and CCU |
MINOCYCLINE | Tablet | 50mg | Y | |
MINOCYCLINE | Injection | 100mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Prescribing to be restricted to Infectious disease (IFD) in susceptible infections for patients in whom other alternatives are inappropriate |
MINOXIDIL | Tablet | 10mg | Y | |
MIRTAZAPINE | Orally disintegrating tablet & tablets | 15mg, 30mg & 45mg | Y | |
MISOPROSTOL | Tablet | 200mcg | Y | |
MITOMYCIN | Eye drop | 0.02% | R | Restricted to Ophthalmologist use only |
MITOMYCIN | Bladder instillation Syringe | 40mg | R | Restricted to Urologist |
MITOMYCIN | Injection | R | 0.02% & 0.05% for Ophthalmologist use. Oncologist use for treatment of Anal Cancer. | |
MITOZANTRONE | Injection | 20mg/10mL & 25mg/12.5mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
MIVACURIUM | Injection | 20mg/10mL | Y | |
MMR VACCINE | Injection | Y | ||
MOMETASONE FUROATE | Nasal Spray | 50mcg | Y | |
MOMETASONE FUROATE | Lotion | 1% | Y | |
MONKEYPOX (Jynneos®) VACCINE | R | Stock via National Medicines Stockpile (NMS). | ||
MONKEYPOX VIRUS TREATMENTS | R | Restricted for use by Infectious Diseases and/or Sexual Health physicians. Approved treatments are Tecovirimat 200mg capsules (Tpoxx®), Vaccinia Immunoglobulin (VIG) ≥50,000 units/15mL and Cidofovir 375mg/5mL injection vials (Empovir®). Stock is managed via National Medicines Stockpile (NMS). NMS approval required prior to access. | ||
MORPHINE HCl MIXTURE | Mixture | 1mg/mL & 5mg/mL | Y | |
MORPHINE INTRATHECAL | Injection | 500microgram/mL | R | Restricted for use by anaesthetics for patients requiring spinal anaesthetic undergoing a caesarean section or as an adjunct analgesia for patients undergoing major surgery |
MORPHINE SULFATE | Injection | 10mg & 30mg | Y | Blanket outpatient approval for Palliative care patients. |
MORPHINE SULFATE (Kapanol®) | Capsule | 10mg, 20mg, 50mg & 100mg | Y | |
MORPHINE SULPHATE (MS Contin®) SLOW RELEASE | Slow Release Tablets | 5mg, 10mg, 30mg, 60mg & 100mg | Y | |
MORPHINE TATRATE | Injection | 120mg | R | Restricted to palliative care and pain team Blanket outpatient approval for Palliative care patients. |
MOXIFLOXACIN | Tablet & Injection | 400mg & 400mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for treatment of infections approved by IFD (for oral form). |
MOXONIDINE | Tablet | 200mcg | Y | |
MULTI-B VITAMINS (Cenovis Mega-B®) | Tablet | Y | ||
MULTIVITAMIN & MINERALS (Cenovis®) | Tablets | Y | ||
MULTIVITAMIN (CERNEVIT) | Injection | Y | ||
MULTIVITAMIN (Pentavite Infant®) | Infant drops | Y | ||
MULTIVITAMIN WITH IRON (Pentavite®) | Syrup | Y | ||
MULTIVITAMINS PLUS ZINC (VitABDECK®) | Capsule | R | Vitamin for Cystic Fibrosis patients. Blanket outpatient approval as a vitamin for Cystic Fibrosis patients. | |
MUPIROCIN | Ointment & Nasal Ointment | 2% | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
MYCOPHENOLATE MOFETIL | Capsule | 250mg & 500mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Formulary for renal transplant use |
MYCOPHENOLATE MOFETIL | Injection | 500mg | Y | |
MYCOPHENOLATE SODIUM (MYFORTIC®) | Tablet | 180mg & 360mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Restricted for use in Lupus Nephritis HSD indications only. The capsules are the formulary mycophenolate option for renal transplant indications. |
NALOXONE | Injection | 400mcg | Y | |
NALOXONE | Nasal Spray | 1.8mg | R | Restricted to Alcohol and Other Drug (AOD) prescribers for Opioid Pharmacotherapy (OPP) patients |
NALTREXONE | Tablet | 50mg | R | Restricted to Addiction Medicine prescribers for use as an adjunct for the treatment of alcohol dependence. |
NAPHAZOLINE/ PHEIRAMINE (Naphcon-A®) | Eye drop | 0.025%/0.3% | Y | |
NAPROXEN | Tablet | 250mg | Y | |
NAPROXEN | Modified Release Tablet | 1g | Y | |
NATALIZUMAB | Injection | 300mg/15mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
NATAMYCIN | Eye drop | 5% | Y | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
NEBIVOLOL | Tablet | 1.25mg, 5mg | Y | Restricted to PBS criteria. |
NEISSERIA MENINGITIDIS/HAEMOPHILUS INFLUENZAE TYPE B (HIB) (Menitorix®) | Injection | 5microg/5microg | Y | |
NEOSTIGMINE | Injection | 500mcg & 2.5mg | Y | |
NETUPITANT/PALONOSETRON | Capsules | 300mcg/500mcg | R | Restricted to Haematology and Oncology for PBS listed indications. |
NEVIRAPINE | Tablet | 200mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
NEVIRAPINE | Modified Release Tablet | 400mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
NICORANDIL | Tablet | 10mg & 20mg | Y | |
NICOTINE | Inhaler | 15mg | Y | |
NICOTINE | Patch | 7mg, 14mg & 21mg | Y | |
NICOTINE | Gum | 2mg & 4mg | Y | |
NICOTINE | Oral Strips | 2.5mg | R | Restricted to Remote Health |
NIFEDIPINE | Tablet | 10mg & 20mg | Y | |
NIFEDIPINE MR | Modified Release Tablet | 30mg & 60mg | Y | |
NIMODIPINE | Injection | 10mg | Y | |
NIMODIPINE | Tablet | 30mg | Y | |
NITAZOXANIDE | Suspension | 100mg/5mL | Y | |
NITRIC OXIDE | Inhalation | 800ppm | Y | |
NITROFURANTOIN | Capsule | 50mg & 100mg | Y | |
NIVOLUMAB | Infusion | Variable | R | Restricted to Medical Oncologists for use in patients enrolled in the Nivolumab Extended Access Program. |
NORADRENALINE | Injection | 2mg | Y | |
NORETHISTERONE | Tablet | 5mg | Y | |
NORFLOXACIN | Tablet | 400mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
NYSTATIN | Capsules | 500 000 units | Y | |
NYSTATIN | Oral drops | 100 000 units | Y | |
OCTREOTIDE | Depot Injection | 10mg, 20mg & 30mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
OCTREOTIDE | Injection | 50mcg, 100mcg & 500mg | Y | |
OFLOXACIN | Eye drop | 3mg | R | Restricted to Ophthalmologist use only |
OLANZAPINE | Tablet | 2.5mg, 5mg & 10mg | Y | |
OLANZAPINE | Injection | 10mg | R | Restricted to Mental Health & ED |
OLANZAPINE (Zyprexa Zydis®) | Wafers | 5mg, 10mg. 15mg & 20mg | Y | |
OLANZAPINE PAMOATE (Zyprexa Relprevv®) | Long Acting Injection | 210mg, 300mg & 405mg | R | Restricted to Mental Health |
OLIVE OIL | Liquid | Y | ||
OMEPRAZOLE | Solution | 2mg/mL | Y | Manufactured at RDH. Blanket outpatient approval for administration via NG/PEG tube in paediatric patients. |
OMEPRAZOLE | Injection | 40mg | Y | Pantoprazole is first line therapy |
OMEPRAZOLE | Tablet | 10mg & 20mg | Y | Pantoprazole is first line therapy |
ONDANSETRON | Injection | 4mg & 8mg | Y | |
ONDANSETRON | Wafers | 4mg & 8mg | Y | |
OPSITE SPRAY DRESSING | Spray | Y | ||
ORABASE (CARMELLOSE/ PECTIN/ GELATIN) | Paste | Y | ||
ORAL REHYDRATION SALTS SOLUTION | Sachets Ice Blocks | Y | ||
OSELTAMIVIR | Liquid | 6mg/mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
OSELTAMIVIR (Tamiflu®) | Capsule | 30mg & 75mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
OXALIPLATIN | Injection | 50mg, 100mg & 200mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
OXAZEPAM | Tablet | 15mg & 30mg | Y | |
OXYBUPROCAINE | Minims | 0.40% | Y | |
OXYBUTYNIN | Tablet | 5mg | Y | |
OXYCODONE | Liquid | 5mg/5mL | Y | |
OXYCODONE (Endone®) | Tablet | 5mg | Y | |
OXYCODONE (Oxycontin SR ®) | Slow Release Tablets | 10mg, 15mg 20mg, 30mg, 40mg & 80mg | Y | NB: Not all strengths are stocked at all sites |
OXYCODONE (Oxynorm®) | Capsule | 10mg & 20mg | Y | |
OXYCODONE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE DIHYDRATE (Targin®) | Tablet | 5/2.5mg, 10/5mg, 20/10mg & 40/20mg | R | Restricted to chronic pain when opioid-induced constipation is refractory to optimised regular laxatives |
OXYCODONE | Intravenous | 50mg/mL | R | Restricted to Acute Pain Service/Anaesthetics for Patient Controlled Analgesia (PCA) |
OXYMETAZOLINE | Nasal Spray | 0.05% | Y | |
OXYTOCIN | Injection | 10units | Y | |
PACLITAXEL | Injection | 30mg, 100mg, 150mg & 300mg | R | Restricted to Haematology and Oncology for PBS listed indications AND advanced or recurrent endometrial cancer, AND as neoadjuvant upper GI with RT. |
PACLITAXEL NANOPARTICLE ALBUMIN BOUND | Injection | 100mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
PALACOS R BONE CEMENT with GENTAMICIN | Cement | Y | ||
PALIPERIDONE | Modified Release Tablet | 3mg, 6mg & 9mg | R | Restricted to Mental Health |
PALIPERIDONE PALMITATE 1 MONTHLY | Depot injection | 25mg, 50mg, 75mg, 100mg & 150mg | R | Restricted to Mental Health |
PALIPERIDONE PALMITATE 3 MONTHLY | Depot injection | 175mg, 263mg, 350mg & 525mg | R | Restricted to Mental Health. For initiation in the outpatient setting only in patients who meet PBS criteria. |
PALONOSETRON | Injection | 250mcg/5mL | R | Restricted to Haematology and Oncology for prevention of nausea and vomiting induced by moderately emetogenic chemotherapy protocols. |
PAMIDRONATE DISODIUM | Injection | 15mg & 90mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
PANCURONIUM | Injection | 4mg | Y | |
PANITUMUMAB | Injection | 100mg/5mL & 400mg/20mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
PANTHENOL/BENZALKONIUM CHLORIDE (BEPANTHEN®) | Cream | 5%/0.05% | Y | |
PANTOPRAZOLE | Tablet | 20mg & 40mg | Y | |
PANTOPRAZOLE | Injection | 40mg | Y | |
PAPAVERINE | Injection | 120mg | Y | |
PARACETAMOL | Tablet | 500mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
PARACETAMOL | Suppositories | 125mg, 250mg & 500mg | Y | |
PARACETAMOL | Drops & Elixir | 100mg/mL & 240mg/5mL | Y | |
PARACETAMOL | Soluble Tablet | 500mg | Y | |
PARACETAMOL | Injection | 1000mg | R | Restricted for post-surgery and patients unable to tolerate oral or rectal route |
PARACETAMOL & CODEINE | Tablet | 500mg/30mg | Y | |
PARACETAMOL MR | Modified Release Tablet | 665mg | R | Restricted to Palliative Care & Remote Health |
PARAFFIN CO | Eye ointment | 3.5g | Y | |
PARAFFIN EMULSION (Parachoc®) | Oral Liquid | 2.5mL/5mL | Y | |
PARAFFIN STERILE | Sterile Liquid | 5g | Y | |
PARAFFIN WHITE SOFT | Cream | 10g (sterile), 50g & 500g | Y | |
PARAFFIN WHITE SOFT & LIQUID PARAFFIN | Ointment | 50%/50% | Y | |
PARALDEHYDE | Injection | Y | NB: Not stocked at all sites. May need to be ordered on a case by case basis. | |
PARECOXIB SODIUM | Injection | 40mg | R | Restricted to Pain team and ICU |
PATENT BLUE VIOLET 2.5% | Pre-Filled Syringe | 2.50% | Y | |
PATIROMER | Sachets | 8.4g | R | Restricted to renal team/nephrologists for short-term use in patients with End Stage Renal Disease on haemodialysis where renal replacement therapy is not accessible. |
PAW-PAW OINTMENT | Ointment | Y | ||
PAZOPANIB | Tablet | 200mg & 400mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
PEGFILGRASTIM | Injection | 6mg/0.6mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
PEMETREXED | Injection | 100mg & 500mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
PENTAMIDINE | Injection | 300mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Restricted to haematology/oncology patients and others under the management /recommendation of IFD |
PEPPERMINT | Lip Balm | 20g | R | Restricted to Palliative Care only |
PERHEXILINE | Tablet | 100mg | Y | |
PERINDOPRIL | Tablet | 2.5mg, 5mg & 10mg | Y | |
PERINDOPRIL ARGININE & INDAPAMIDE | Tablet | 5mg/1.25mg | Y | |
PERMETHRIN | Cream | 5% | Y | |
PHENTERMINE | Tablet | 15mg | R | Blanket outpatient approval for RDPH Weight Management Clinic |
PHENTOLAMINE MESYLATE | Injection | 5mg | R | Restricted to Emergency Department for the treatment of dermal necrosis and sloughing following intravenous administration or extravasation of noradrenaline or adrenaline. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
PHENOBARBITAL | Injection | 200mg | Y | |
PHENOBARBITAL | Tablet | 30mg | Y | |
PHENOBARBITAL | Syrup | 15mg/5mL | Y | |
PHENOXYMETHYLPENICILLIN | Capsule | 250mg & 500mg | Y | |
PHENOXYMETHYLPENICILLIN (PENICILLIN V) | Suspension | 150mg/5mL | Y | |
PHENYLEPHRINE | Minims | 2.5% & 10% | Y | |
PHENYTOIN | Injection | 100mg & 250mg | Y | |
PHENYTOIN | Chewable tablets | 50mg | Y | |
PHENYTOIN | Capsule | 30mg & 100mg | Y | |
PHENYTOIN | Suspension | 30mg/5mL | Y | |
PHOSPHATE (Fleet®) | Enema | 133mL | Y | |
PHOSPHATE, SODIUM ACID (Phosphate Sandoz®) | Effervescent Tablet | 500mg | Y | |
PHYSOSTIGMINE | Injection | 2mg | Y | |
PHYTOMENADIONE (Vitamin K®) | Injection | 2mg & 10mg | Y | Blanket outpatient approval. |
PILOCARPINE | Minims | 2% | R | Restricted to eye department |
PILOCARPINE (with preservative) | Eye drop | 1%, 2% & 4% | Y | |
PIMECROLIMUS | Cream | 1% | R | For patients who fail to hydrocortisone 1% cream/ointment. |
PIPERACILLIN & TAZOBACTAM | Infusor | Variable | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
PIPERACILLIN & TAZOBACTAM | Injection | 4g/0.5g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
PIROXICAM | Capsule | 10mg | Y | |
PLASMA-LYTE 148 in WATER | IV fluid | Y | ||
PLASMA-LYTE 148 with GLUCOSE 5% | IV fluid | 1 L | R | For paediatric use |
PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE (Paediatric) | Injection | Y | ||
PNEUMOCOCCAL VACCINE 23 VALENT (Adult) | Injection | Y | ||
PODOPHYLLOTOXIN | Solution | 0.50% | Y | |
PODOPHYLLOTOXIN | Cream | 0.15% | Y | |
POLIOMYELITIS VACCINE (Ipol®) | Injection | Y | ||
POLOXAMER | Drops | 100mg/mL | Y | |
POLYMYXIN B | Injection | 500,000 units | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Prescribing to be restricted to Infectious disease (IFD) in susceptible infections for patients in whom other alternatives are inappropriate |
POLYVINYL ALCOHOL | Eye drops | 1.40% | Y | |
PORACTANT | Suspension for intratracheal administration | 240mg/3mL | Y | |
POSACONAZOLE | Modified Release Tablet & Oral Suspension | 100mg & 40mg/mL (105mL) | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for non-PBS indications, restricted to Haematology and Oncology/ Infectious Diseases. |
POSACONAZOLE | Injection | 300mg/16.7mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
POTASSIUM ACETATE | Injection | 25mmol | Y | |
POTASSIUM CHLORIDE | Effervescent tablets | 14mmol | Y | |
POTASSIUM CHLORIDE | Injection | 10mmol/10mL | Y | |
POTASSIUM CHLORIDE | Modified Release Tablet | 600mg | Y | |
POTASSIUM CHLORIDE FOR DIALYSIS | Solution | 26.1%w/v | Y | |
POTASSIUM CHLORIDE in GLUCOSE | IV fluid | 10mmol/10% in 500mL | Y | |
POTASSIUM CHLORIDE in SODIUM CHLORIDE | IV fluid | 10mmol/0.29% in 100mL, 20mmol/0.9% in 1000mL, 30mmol/0.9% in 1000mL, 40mmol/0.9% in 1000mL | Y | |
POTASSIUM CHLORIDE in SODIUM LACTATE COMPOUND | IV fluid | 30mmol in 1L | Y | |
POTASSIUM CHLORIDE in SODIUM CHLORIDE with GLUCOSE | IV fluid | 20mmol/0.18%/4% in 1L, 20mmol/0.9%/5% in 1L, 40mmol/0.9%/5% in 1L, 10mmol/0.225%/ 10% in 500mL | Y | |
POTASSIUM DIHYDROGEN PHOSPHATE | Injection | 10mmol/10mL | R | Wards can contact pharmacy or ICU liaison if further support is required |
POTASSIUM PERMANGANATE | Crystals | Y | ||
POVIDONE IODINE | Solution | 7.50% | Y | |
POVIDONE IODINE | Scrub Brush | Y | ||
POVIDONE IODINE | Ointment Sachets | 10% | Y | |
POVIDONE IODINE (100mL) | Solution | 10% | Y | |
POVIDONE IODINE ALCOHOLIC | Skin Preparation | Y | ||
PRALIDOXIME IODIDE | Injection | 500mg | Y | |
PRAMIPEXOLE | Tablet | 180mcg & 250mcg | R | Restricted to remote patients with Machado Joseph Disease |
PRAZIQUANTEL | Tablet | 600mg | Y | Blanket approval for outpatient supply. Restricted to the treatment of Hymenolepsis nana (dwarf tape worm) infection. |
PRAZOSIN | Tablet | 1mg, 2mg & 5mg | Y | |
PREDNISOLONE | Tablet | 1mg, 5mg & 25mg | Y | Blanket approval for outpatient supply. Restricted to: Haematology/Oncology. |
PREDNISOLONE | Suspension | 25mg/5mL | Y | |
PREDNISOLONE & PHENYLEPHRINE (PREDNEFRIN FORTE EYE®) | Eye drops | 1%/0.12% | Y | |
PREDNISOLONE ENEMA | Enema | 0.2mg/mL | Y | |
PREDNISOLONE SODIUM PHOSPHATE | Eye drop minims | 0.5% | R | Restricted to use by ophthalmology. Blanket outpatient approval for patients with allergy to preservatives in prednisolone containing eye drops or for patients where prednisolone as a single ingredient is required. |
PREGABALIN | Capsule | 25mg, 75mg & 150mg | R | Blanket outpatient approval for neuropathic pain for patients with fibromyalgia syndrome only. Prescriber to annotate script as “fibromyalgia syndrome/non-PBS indication”. |
PREGNANCY TEST | Strip | Y | ||
PRILOCAINE | Injection | 0.50% | Y | |
PRIMAQUINE | Tablet | 7.5mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for prevention or relapse of malaria or treatment of Pneumocystis carinii pneumonia (PCP). |
PRIMIDONE | Tablet | 250mg | Y | |
PROBENECID | Tablet | 500mg | Y | |
PROCARBAZINE | Capsule | 50mg | R | Restricted to Haematology and Oncology for BEACOPP (Hodgkin Lymphoma) AND PCV (Neuro). |
PROCHLORPERAZINE | Injection | 12.5mg/5mL | Y | |
PROCHLORPERAZINE | Tablet | 5mg | Y | |
PROGESTERONE | Pessaries | 200mg | R | Restricted to O&G for PBS listed indications. |
PROMETHAZINE | Elixir | 1mg/mL | Y | |
PROMETHAZINE | Tablet | 10mg & 25mg | Y | |
PROMETHAZINE | Injection | 50mg | R | Restricted to haematology/oncology patients on chemotherapy requiring hypersensitivity reaction rescue AND remote primary health care for indications outlined in CARPA |
PROPANTHELINE | Tablet | 15mg | Y | |
PROPOFOL | Injection | 200mg & 500mg | Y | |
PROPRANOLOL | Suspension | 10mg/5mL | Y | |
PROPRANOLOL | Tablet | 10mg, 40mg & 160mg | Y | |
PROPYLENE GLYCOL | Solution | Y | ||
PROPYLTHIOURACIL | Tablet | 50mg | Y | |
PROTAMINE SULPHATE | Injection | 50mg/5mL | Y | |
PSEUDOEPHEDRINE | Tablet | 60mg | Y | |
PSYLLIUM | Powder | Y | ||
PYRANTEL | Tablet | 125mg | Y | |
PYRAZINAMIDE | Tablet | 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of tuberculosis by TB clinic/IFD. |
PYRIDOSTIGMINE | Tablet | 10mg & 60mg | Y | |
PYRIDOXINE | Tablet | 25mg | Y | Blanket outpatient approval for the prevention of isoniazid-induced peripheral neuropathy. |
PYRIMETHAMINE | Tablet | 25mg | Y | |
QUETIAPINE | Tablet | 25mg, 100mg, 200mg & 300mg | Y | |
QUETIAPINE | Modified Release Tablet | 50mg, 200mg & 300mg | Y | |
RABIES VACCINE | Injection | Y | ||
RALTEGRAVIR | Tablet | 400mg 600mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RALTITREXED | Injection | 2mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
RAMIPRIL | Tablet & capsules | 1.25mg, 2.5mg, 5mg & 10mg | Y | |
RANIBIZUMAB | Injection | 2.3mg & 3mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RASBURICASE | Injection | 1.5mg/1mL | R | Restricted to use in Haematology and Oncology for the treatment of acute hyperuricaemia of presumed or confirmed tumour lysis syndrome, in accordance with approved guidelines. |
REMDESIVIR | Injection | 100mg | R | Restricted to prescribing by ICU and IFD Physicians for COVID – 19 Patients on ICU and 4B who are 12 years or older and weigh at least 40kg with pneumonia and requiring supplemental oxygenation. |
REMIFENTANIL | Injection | 1mg & 5mg | Y | |
RETEPLASE | Injection | 10 units | Y | Short-term listing for thrombolysis in acute STEMI while tenecteplase is out of stock. |
RIBAVIRIN (Ibavyr®) | Tablet | 200mg | S | Restricted to specialists working in the liver clinic running the HCV treatment program. For initiation in outpatients via the Highly specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RIFABUTIN | Capsule | 150mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RIFAMPICIN | Syrup | 100mg/5mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
RIFAMPICIN | Injection | 600mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
RIFAMPICIN | Capsule | 150mg & 300mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
RIFAPENTINE | Tablet | 150mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for the treatment of latent tuberculosis by TB clinic/IFD. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
RIFAXIMIN | Tablet | 550mg | Y | Restricted to PBS indications. |
RILPIVIRINE | Tablet | 25mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RISPERIDONE | Solution | 5mg/5mL | Y | |
RISPERIDONE | Tablet | 0.5mg, 1mg 2mg, 3mg & 4mg | Y | |
RISPERIDONE (CONSTA®) | Depot Injection | 25mg, 37.5mg & 50mg | R | Restricted to Mental Health for continuing treatment in patients already stabilised on Risperidone depot, or initial treatment in patients where paliperidone depot is unsuitable or not tolerated. |
RITONAVIR | Tablet | 100mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RITUXIMAB | Injection | 100mg/10mL, 500mg/50mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
RITUXIMAB | Infusion | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. | |
RIVAROXABAN | Tablets | 10mg,15mg & 20mg | R | Restricted to PBS indications. |
RIZATRIPTAN | Wafer | 10mg | Y | Short-term listing while oral zolmitriptan is out of stock. |
ROCURONIUM | Injection | 50mg | Y | |
ROPIVACAINE | Injection | 75mg/10mL | Y | Other strengths are available on request. |
ROSUVASTATIN | Tablets | 5mg, 10mg, 20mg & 40mg | Y | |
ROTAVIRUS ORAL VACCINE | Oral Solution | Y | ||
ROXITHROMYCIN | Tablet | 150mg | Y | |
SACUBITRIL WITH VALSARTAN | Tablet | 24mg/26mg, 49mg/51mg, 97mg/103mg | Y | Restricted to PBS indications. |
SALBUTAMOL | Injection | 500mcg | Y | |
SALBUTAMOL | Nebuliser | 2.5mg & 5mg | Y | |
SALBUTAMOL | Inhaler | 100mcg | Y | |
SALICYLIC ACID / COAL TAR in AQUEOUS CREAM | Cream | 6%/6% | Y | |
SALICYLIC ACID/ LACTIC ACID | Paint | 16.70% | Y | |
SALINE LAXATIVE (Fleet®) FLEET | Mixture & Enema | Y | ||
SALIVA ARTIFICIAL | Solution | Y | ||
SEMAGLUTIDE | Syringe | 1.34mg/mL (1.5mL & 3mL) | R | Restricted to PBS indications. (Use restricted to continuation treatment only; Treatment initiation requires IPU approval) |
SENNA | Tablets | 7.5mg | Y | |
SERTRALINE | Tablets | 50mg & 100mg | Y | |
SEVELAMER | Tablets | 800mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SEVOFLURANE | Liquid for inhalation | Y | ||
SILDENAFIL | Injection | 10mg/12.5ml | R | Restricted to ICU use only for patients with pulmonary arterial hypertension. |
SILDENAFIL | Tablets | 20mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SILVER NITRATE/POTASSIUM NITRATE | Pencil & Sticks | 427.5mg/22.5mg | Y | |
SILVER SULPHADIAZINE | Cream | 1% | Y | |
SIMETHICONE | Drops | 100mg/mL | Y | |
SIMETHICONE | Liquid | 120mg/mL | Y | *For short-term listing while drops are out of stock |
SIMVASTATIN | Tablet | 10mg, 20mg 40mg & 80mg | Y | |
SIROLIMUS | Tablet | 0.5mg, 1mg & 2mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SITAGLIPTIN | Tablet | 25mg, 50mg & 100mg | Y | |
SOAP ENEMA | Enema | 5% | Y | |
SODA LIME (Medisorb®) | Prepacked Canister | Y | ||
SODIUM BENZOATE | Injection | 2g/10mL | R | Restricted to Paediatricians under the advice of a Metabolic Specialist for the emergency treatment of hyperammonaemia in urea cycle defects. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
SODIUM BICARBONATE | Capsule | 840mg | Y | |
SODIUM BICARBONATE | Injection & Mini-jet | 100mmol | Y | Mini-jet is restricted to resuscitation room in the emergency department |
SODIUM CHLORIDE | Tablets | 600mg | Y | |
SODIUM CHLORIDE | Injection | 0.9%/5% (1L) | Y | |
SODIUM CHLORIDE | Eye Drops | 5% | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. Blanket outpatient approval for corneal oedema. |
SODIUM CHLORIDE | Injection | 0.45% (500mL), 0.9% (10mL, 20mL, 50mL, 100mL, 250mL, 500mL, 1L & 2L), 3% (1L), 23.4% (10mL), | Y | |
SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, GLUCOSE ANHYDROUS, CALCIUM LACTATE PENTAHYDRATE (Flo®) | Nasal Sachets/ Irrigation kit | R | Restricted to ENT and Radiation Oncology | |
SODIUM CHONDROITIN SULPHATE/SODIUM HYALURONATE (Viscoat®) | Eye Irrigation | 40mg/30mg/mL | Y | |
SODIUM CITRATE | Solution | 8.80% | Y | |
SODIUM CITRATE/ SODIUM LAURYL SULFOACETATE (Microlax®) | Enema | 90mg/9mg/mL | Y | |
SODIUM CITRO-TARTRATE | Sachets | Y | ||
SODIUM CROMOGLYCATE | Eye Drops | 2% | Y | |
SODIUM DIHYDROGEN PHOSPHATE | Injection | 10mmol/10mL | Y | |
FUSIDIC ACID HEMIHYDRATE | Tablet | 250mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
SODIUM HYALURONATE (Provisc®) | Intraocular Injection | 8.5mg/0.85mL | Y | |
SODIUM LACTATE CO (Hartmann’s®) | IV fluid | Y | ||
SODIUM NITROPRUSSIDE | Injection | 50mg | Y | |
SODIUM PICOSULFATE | Oral liquid | 7.5mg/mL | R | Restricted to palliative care. |
SODIUM PICOSULFATE, MAGNESIUM OXIDE & CITRIC ACID (Picoprep®) | Sachets | Y | ||
SODIUM POLYSTYRENE SULFONATE (Resonium A®) | Powder | 454g | Y | |
SODIUM SULFATE DECAHYDRATE / MACROGOL/ ELECTROLYTES (COLONLYTELY®) | Sachets | Y | ||
SODIUM TETRADECYL SULPHATE | Injection | 3% | Y | |
SODIUM THIOSULFATE | Injection | 25g/100mL | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. Blanket outpatient approval for calciphylaxis, restricted to nephology. |
SODIUM VALPROATE | Injection | 400mg | Y | |
SODIUM VALPROATE | Suspension | 200mg/5mL | Y | |
SODIUM VALPROATE | Chewable tablets | 100mg | Y | |
SODIUM VALPROATE | Enteric Coated Tablet | 200mg & 500mg | Y | |
SOFOSBUVIR/VELPATASVIR (Epclusa®) | Tablet | 400mg/100mg | S | Restricted to specialists working in the liver clinic running the HCV treatment program. For initiation in outpatients via the Highly specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SOFOSBUVIR/VELPATASVIR/ VOXILAPREVIR (VOSEVI®) | Tablet | 400mg/100mg/ 100mg | S | Restricted to specialists working in the liver clinic running the HCV treatment program. For initiation in outpatients via the Highly specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SOMATROPIN | Injection | 1mg, 8mg, 10mg & 12mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SORAFENIB | Tablet | 200mg | R | Restricted to Haematology and Oncology for PBS listed indications. Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
SORBITOL | Solution | 70% | Y | |
SOTALOL | Injection | 40mg | Y | |
SOTALOL | Tablet | 80mg & 160mg | Y | |
SPACER – DISPOSABLE | R | For use by Emergency Department and NCCRTC only. | ||
SPACER FOR AEROSOL | Y | |||
SPILL KIT FOR CYTOTOXIC DRUGS | Y | |||
SPIRONOLACTONE | Tablet | 25mg & 100mg | Y | |
SPIRONOLACTONE | Solution | 12.5mg/5mL | Y | |
STREPTOMYCIN | Injection | 1g | Y | |
SUCROFERRIC OXYHYDROXIDE | Chewable tablet | 2.5 g | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
SUCROSE | Oral Solution | 24% | Y | |
SUFENTANIL | Injection | 50mcg | R | This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. Blanket outpatient approval for cancer pain. |
SUGAMMADEX | Injection | 200mg | R | Restricted to use by Anaesthetic, ICU and ED specialists only. |
SULFASALAZINE | Enteric Coated Tablet | 500mg | Y | |
SULPHAMETHOXAZOLE/ TRIMETHOPRIM (Bactrim®) | Suspension | 200mg/40mg/ 5mL | Y | |
SULPHAMETHOXAZOLE/ TRIMETHOPRIM (Bactrim®) | Tablet | 400mg/80mg & 800mg/160mg | Y | Blanket outpatient approval for melioidosis eradication and Pneumocystis carinii pneumonia (PCP). Restricted to: Haematology/Oncology and Infectious Diseases. |
SULPHAMETHOXAZOLE/ TRIMETHOPRIM (Bactrim®) | Injection | 400mg/80mg | Y | |
SUNITINIB | Capsule | 12.5mg, 25mg & 50mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
SUNSCREEN SPF | Lotion | 15+, 30+ | Y | |
SUNSCREEN with ZINC | CREAM | 50+ | Y | |
SUXAMETHONIUM | Injection | 100mg | Y | |
TACROLIMUS | Capsule | 500mcg, 1mg & 5mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
TACROLIMUS XL | Extended Release Capsule | 500mcg, 1mg, 3mg & 5mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
TALC (STERILE LARGE PARTICLE) (Steritalc®) | Powder | 4g | Y | |
TAMOXIFEN | Tablet | 10mg & 20mg | Y | |
TAMSULOSIN | Tablets | 400mcg | R | Restricted to urologists and geriatricians. Restricted ONLY for the treatment of benign prostate hypertension (BPH) in patients where prazosin is not appropriate or not tolerated. |
TAPENTADOL IR | Immediate Release Tablet | 50mg | R | Restricted to; Continuing inpatient use (regular medicine) OR Initiation of treatment by Acute Pain Service, Geriatricians or Rehabilitation Consultants that meet the following; Inpatient use only AND Patients with severe incident-pain and complex pain management needs where its use will form part of a multimodal analgesic regimen AND Patient has contraindications to the use of tramadol (indicate reason) Taking other medication with serotonergic effects At risk of seizures (Note: Tapentadol should be prescribed with care in patient at risk of seizures) Other (reasons to be provided) AND Plan for analgesia requirements on discharge has been considered and documented if required. Tapentadol immediate release tablets cannot be supplied on discharge from hospital |
TAPENTADOL SR | Slow Release Tablet | 50mg, 100mg, 150mg, 200mg & 250mg | R | Restricted to PBS indications. |
TEA TREE | Oil | Y | ||
TEICOPLANIN | Injection | 400mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
TEMAZEPAM | Tablet | 10mg | Y | |
TEMOZOLOMIDE | Capsule | 5mg, 20mg, 100mg, 140mg, 180mg & 250mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
TENECTEPLASE | Injection | 50mg | Y | Restricted for acute myocardial infarction in the settings of pre-hospital thrombolysis (e.g. ambulance service, Careflight, RFDS), small rural hospitals (GDH, KDH, Tennant Creek Hospital), Alice Springs Hospital and remote facilities (Aboriginal health services). |
TENOFOVIR DISOPROXIL | Tablet | 300mg OR 291mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Blanket outpatient approval for management of Hepatitis B in pregnancy. |
TENOFOVIR DISOPROXIL & EMTRICITABINE | Tablet | 300mg+200mg OR 291mg+200mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
TENOFOVIR DISOPROXIL, EMTRICITABINE & EFAVIRENZ | Tablet | 300mg+200mg+ 600mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
TERBINAFINE | Tablet | 250mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
TERBINAFINE | Cream | 1% | R | Restricted to indications meeting PBS criteria. |
TERBUTALINE | Injection | 500mcg/mL | R | Restricted to use in obstetrics for pregnant women with foetal distress requiring immediate delivery, or prior to External Cephalic Version (ECV) |
TERBUTALINE | Turbuhaler | 500mcg | Y | |
TERLIPRESSIN | Injection | 0.85mg/mL | R | Restricted to Emergency Physicians, Intensive Care Physicians and Gastroenterologists for haemorrhaging oesophageal varices. Restricted to Intensive Care Physicians, Gastroenterologists and Nephrologists for Type 1 Hepatorenal Syndrome. |
TESTOSTERONE ESTERS | Injection | 100mg & 250mg | Y | |
TETRABENAZINE | Tablet | 25mg | Y | |
TETRACAINE (AMETHOCAINE) HYDROCHLORIDE | Minims | 1% | Y | |
TETRACAINE (AMETHOCAINE) HYDROCHLORIDE | Gel | 4% | Y | |
TETRACAINE (AMETHOCAINE) HYDROCHLORIDE / LIDOCAINE/ ADRENALINE (EPINEPHRINE) (LACERAINE®) | Gel | 40mg/5mg/1mg/5mL | Y | |
TETRACAINE (AMETHOCAINE) / LIDOCAINE/ ADRENALINE (EPINEPHRINE) | Injection | 0.5%/ 4%/ 1:1000 | Y | |
TETRACOSACTIDE (TETRACOSACTRIN) (Synacthen®) | Injection | 250mcg & 1mg | Y | |
THALIDOMIDE | Capsule | 50mg, 100mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
THEOPHYLLINE | Modified Release Tablet | 200mg, 250mg & 300mg | Y | |
THIAMINE | Tablet | 100mg | Y | |
THIAMINE | Injection | 300mg | Y | |
THIOPENTONE | Injection | 500mg | Y | |
THROMBIN | Injection | 5000units | Y | |
THYMOL | Mouthwash | Y | ||
TICAGRELOR | Tablet | 90mg | R | Restricted to Cardiologists & Interventional Cardiologists for patients undergoing planned PCI and CABG, and for patients who have had a cardiac event whilst taking clopidogrel. |
TIGECYCLINE | Injection | 50mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
TIMOLOL | Eye Drops | 0.25% & 0.5% | Y | |
TIMOLOL LA | Long Acting Eye drops | 0.50% | Y | |
TIOGUANINE | Tablet | 40mg | R | Restricted to Haematology and Oncology for PBS listed indications. Blanket approval for outpatient supply with PBS prescription. Restricted to: Haematology/Oncology. |
TIOTROPIUM | Capsules for Inhalation | 18mcg | Y | |
TIOTROPIUM | Inhaler | Y | ||
TIROFIBAN | Injection | 12.5mg | R | Restricted to Cardiology |
TOBRAMYCIN | Injection | 80mg (with preservative & preservative free for inhalation) & 500mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
TOBRAMYCIN | Eye drops | 0.3% & 1.4% (1.4% compounded) | R | Restricted to Ophthalmologist use only. Blanket outpatient approval for treatment or prevention of ophthalmic infections. |
TOBRAMYCIN | Eye ointment | 0.30% | Y | |
TOCILIZUMAB | Injection | 200mg & 400mg | Restricted to ICU Physicians as per use in REMAP CAP clinical trials only | |
TOPIRAMATE | Sprinkle Capsule | 25mg | Y | |
TOPIRAMATE | Tablet | 25mg, 50mg & 100mg | Y | Blanket outpatient approval for RDPH Weight Management Clinic |
TOPOTECAN | Injection | 4mg | R | Restricted to Haematology and Oncology for PBS listed indications AND Small Cell Lung Cancer, AND Neuroendocrine Unknown Primary Cancer. |
TPN ADULT STD TRIPLE PHASE BAG (SmofKabiven®) | IV fluid | 1970mL | Y | |
TPN NEONATE 34 WEEK TO TERM | IV fluid | 1200mL | Y | Order on request |
TPN NEONATE CONCENTRATED PRETERM | IV fluid | 750mL | Y | Order on request |
TPN NEONATE HIGH SODIUM PRETERM | IV fluid | 750mL | Y | Order on request |
TPN NEONATE PRETERM (7.5% GLUCOSE) | IV fluid | 750mL | Y | Order on request |
TPN NEONATE STANDARD PRETERM | IV fluid | 750mL | Y | RDH Stocked |
TPN NEONATE STARTER | IV fluid | 750mL | Y | RDH Stocked |
TRAMADOL | Capsule | 50mg | Y | |
TRAMADOL | Injection | 100mg | Y | |
TRANEXAMIC ACID | Injection | 1000mg/10mL | Y | |
TRANEXAMIC ACID | Tablet | 500mg | Y | |
TRASTUZUMAB | Injection | 60mg, 150mg, 600mg/5mL | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
TRIAMCINOLONE | Injection | 10mg & 40mg | Y | |
TRIAMCINOLONE | Dental paste | 0.10% | Y | |
TRICLOSAN | Solution | 1% | Y | |
TRIHEXYPHENIDYL (BENZHEXOL) HYDROCHLORIDE | Tablet | 2mg | Y | |
TRIMETHOPRIM | Tablet | 300mg | Y | |
TROPICAMIDE | Minims | 0.5% & 1% | Y | |
TROPONIN | Test strips | Y | ||
TRYPAN BLUE | Injection | 0.10% | Y | |
TUBERCULIN PPD | Injection | 100units/mL | Y | |
ULIPRISTAL ACETATE | Tablet | 30mg | R | Restricted to women who require emergency contraception between 72 to 120 hours after unprotected intercourse or contraception failure (For GDH only). |
UMECLIDINIUM (Ellipta Incruse®) | Inhaler | 62.5mcg | Y | |
UMECLIDINIUM / FLUTICASONE/ VILANTEROL (Ellipta Trelegy®) | Inhaler | 62.5mcg/ 100mcg/ 25mcg | Y | |
UMECLIDINIUM / VILANTEROL (Ellipta Anoro®) | Inhaler | 62.5mcg/ 25mcg | Y | |
UREA & LACTIC ACID (Calmurid®) | Cream | 10%/5% | Y | |
UREA (Dermadrate®) | Cream | 10% | Y | |
UREA (Ure-Na®) | Sachets | 15gm | R | Restricted to Endocrinology. This is a Special Access Scheme (SAS) product. Please complete appropriate SAS form which can be located on the TGA website. |
URINE STRIPS | Strips | |||
UROKINASE | Vial | 5,000 units 10,000 units 25,000 units 100,000 units | Y | Short-term listing for fibrinolytic management of obstructed Central Vascular Access Devices (CVADs). *Strengths subject to availability |
URSODEOXYCHOLIC ACID | Suspension | 250mg/5mL | Y | |
URSODEOXYCHOLIC ACID | Capsule | 250mg | Y | Blanket outpatient approval for obstetric cholestasis. |
USTEKINUMAB | Injection | 130mg and 45mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. Note: The 45mg injection is to be sourced under PBS general schedule for outpatients. |
VALACICLOVIR | Tablet | 500mg | S | Restricted to PBS criteria Blanket inpatient/outpatient approval for viral prophylaxis in haematology patients undergoing suppressive chemotherapy OR Ophthalmic Herpes Simplex. |
VALGANCICLOVIR | Tablet Oral Liquid | 450mg 50mg/mL | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket inpatient/outpatient approval for treatments and prophylaxis of susceptible infections not listed on the PBS approved by Infectious Diseases. |
VANCOMYCIN | Infusor | Variable | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
VANCOMYCIN | Injection | 500mg & 1g | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
VARICELLA ZOSTER (Chicken Pox®) VACCINE | Injection | Y | ||
VECURONIUM | Injection | 4mg, 10mg | Y | |
VEDOLIZUMAB | Injection | 300mg | S | Restricted to Gastroenterologists for Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
VENLAFAXINE | Modified Release Capsule | 37.5mg, 75mg & 150mg | Y | |
VERAPAMIL | Injection | 5mg | Y | |
VERAPAMIL | Tablet | 40mg & 80mg | Y | |
VERAPAMIL | Modified Release Capsule | 180mg & 240mg | Y | |
VINBLASTINE | Injection | 10mg/10mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
VINCRISTINE | Injection | 1mg/mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
VINORELBINE | Capsule | 20mg & 30mg | R | Restricted to Haematology and Oncology for PBS listed indications. |
VINORELBINE | Injection | 10mg/mL, 50mg/5mL | R | Restricted to Haematology and Oncology for PBS listed indications. |
VITAMIN A | Ointment | Y | ||
VITAMIN A (RETINOL PALMITATE) | Capsule | 50,000units | Y | |
VITAMIN B COMPLEX (Cenovis Mega B®) | Tablets | Y | ||
VITAMIN E | Oral Liquid | 156iu | Y | |
VITAMIN PREGNANCY & BREASTFEEDING (I-Folic®) | Tablets | R | Restricted to remote health and maternity inpatients for women who are pregnant or breastfeeding. | |
VORICONAZOLE | Injection | 200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT |
VORICONAZOLE | Tablet | 50mg & 200mg | R | Restricted antimicrobial - Please refer to the Restricted Antimicrobial Guideline NT Blanket outpatient approval for susceptible infections not listed on the PBS approved by Infectious Diseases. |
WARFARIN (Coumadin® Brand) | Tablet | 1mg, 2mg & 5mg | Y | |
WATER FOR INJECTIONS | Injection | 10mL, 20mL & 1L | Y | |
WATER FOR IRRIGATION | Irrigation | 1L & 2L | Y | |
WOOL ALCOHOLS | Ointment | 100g | Y | |
XYLOMETAZOLINE | Nasal Drops | 0.05% | Y | |
ZINC & CASTOR OIL | Cream | 20g | Y | |
ZINC (Elemental) | Capsule | 50mg | Y | |
ZINC OXIDE | Cream | Y | ||
ZINC SULPHATE | Solution | 50mg/mL | Y | Contains elemental Zinc 11.3mg/mL. |
ZOLEDRONIC ACID | Injection | 5mg | Y | Blanket outpatient approval for osteoporosis in patients who don’t meet PBS criteria. |
ZOLEDRONIC ACID | Injection | 4mg | S | Highly Specialised Drugs Program (Section 100). Refer to PBS Criteria. |
ZOLMITRIPTAN | Tablet | 2.5 | Y | |
ZOSTER VACCINE (Shingrix®) | Injection | 0.5mL | Y | For patients eligible under National Immunisation Program (NIP) Schedule only. |
ZUCLOPENTHIXOL ACETATE | Injection | 50mg | R | Restricted to prescribing by or upon consultation with psychiatrists. |
ZUCLOPENTHIXOL | Tablet | 10mg | Y | |
ZUCLOPENTHIXOL DECANOATE | Injection | 200mg | Y |